 
 
 
 
 
 
2546.00: Donor Statin Treatment for Prevention of 
Severe Acute GVHD after Nonmyeloablative 
Hematopoietic Cell Transplantation  
 
[STUDY_ID_REMOVED]  
 
Version 02/06/2018  
  
2546.00  - Nonablative  
1 
FHCRC Current Version:  02/06/2018  
 
         FRED HUTCHINSON CANCER RESEARCH CENTER  
UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE  
SEATTLE CHILDREN’S  
 
Previous version: 02/06/2018  
Current version:  08/04/2017  
 
Title of Protocol:  
Donor Statin Treatment for Prevention of Severe Acute GVHD after  
Nonmyeloablative  Hematopoietic Cell Transplantation  
 
 
 
Investigators List:  
Investigator s Professional Title  Phone Number  
Marco Mielcarek, MD  Member, FHCRC, Professor of Medicine, UW  (206) 667 -2827  
Paul Martin MD  Member, FHCRC, Professor of Medicine, UW  (206) 667 -4798  
Brenda Sandmaier, MD  Member, FHCRC, Professor of Medicine, UW  (206) 667 -4961  
David Maloney, MD, PhD  Member, FHCRC, Professor of Medicine, UW  (206) 667 -5616  
Rainer Storb, MD  Member, FHCRC, Professor of Medicine, UW  (206) 667 -4407  
   
Biostatistician:  
Barry Storer, PhD  Member, FHC RC, Professor of Biostatistics, UW (206) 667 -6151  
Research Staff:  
Michelle Bouvier , RN Research Nurse  (206) 667 -6993  
 
 
 
 
Emergency (24 hour) phone number:  (206) 598 -8902  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2546.00  - Nonablative  
2 
FHCRC Current Version:  02/06/2018  
 
 TABLE OF CONTENTS  
INTRODUCTION  ................................ ................................ ................................ ................................ ........................  6 
BACKGROUND  ................................ ................................ ................................ ................................ .........................  6 
2.1 Immunomodulatory effects of statins.  ................................ ................................ ................................ ....... 6 
2.2 Statins for GVHD -prevention: Preclinical and clinical studies  ................................ ................................ .. 6 
2.3 Rationale for the Current Study  ................................ ................................ ................................ ................  8 
STUDY OBJECTIVES  ................................ ................................ ................................ ................................ ................  9 
3.1 Primary Objective  ................................ ................................ ................................ ................................ ..... 9 
3.2 Secondary Objective  ................................ ................................ ................................ ................................ . 9 
STUDY DESIGN  ................................ ................................ ................................ ................................ ........................  9 
4.1 Description of Study  ................................ ................................ ................................ ................................ .. 9 
4.2 Endpoints  ................................ ................................ ................................ ................................ ..................  9 
PATIENT SELECTION  ................................ ................................ ................................ ................................ ...............  9 
5.1 Inclusion Criteria (If Protocol 2546 serves as an adjunct protocol, the patient only needs to 
meet inclusion criteria 1 through 5A.)  ................................ ................................ ................................ .....................  9 
5.2 Exclusion Criteria (If Protocol 2546 serves as an adjunct protocol, the patient only needs to 
meet exclusion criteria 1 through 3.)  ................................ ................................ ................................ ....................  11 
DONOR SELECTION  ................................ ................................ ................................ ................................ ..............  12 
6.1  Inclusions  ................................ ................................ ................................ ................................ ................  12 
6.2 Exclusions  ................................ ................................ ................................ ................................ ...............  12 
INFORMED CONSENT OF SUBJECT AND DONOR  ................................ ................................ .............................  12 
PATIENT AND DONOR REGISTRATION  ................................ ................................ ................................ ...............  12 
PLAN OF TREATMENT  ................................ ................................ ................................ ................................ ...........  12 
9.1 Donor Treatment with Atorvastatin  ................................ ................................ ................................ .........  12 
9.2 Recipient Treatment (References below to standard practice refer to standard practice at site 
where HCT is being performed.)  ................................ ................................ ................................ ..........................  13 
EVALUATION OF PATIENTS  ................................ ................................ ................................ ................................ .. 20 
10.1  Patient Pre -transplant Evaluation for All Diseases  ................................ ................................ .................  20 
10.2  Patient Post -transplant Evaluation  ................................ ................................ ................................ .........  25 
EVALUATION OF DONORS ................................ ................................ ................................ ................................ .... 40 
11.1 Safety Evaluations  ................................ ................................ ................................ ................................ ........  40 
11.2 Donor Statin Compliance ................................ ................................ ................................ ..............................  40 
TOXICITIES AND COMPLICATIONS  ................................ ................................ ................................ ......................  41 
12.1  Atorvastatin  ................................ ................................ ................................ ................................ .............  41 
12.2  GVHD  ................................ ................................ ................................ ................................ ......................  43 
ADVERSE EVENT MONITORING  ................................ ................................ ................................ ..........................  44 
13.1  Institutional Policy and Definitions  ................................ ................................ ................................ ..........  44 
2546.00  - Nonablative  
3 
FHCRC Current Version:  02/06/2018  
 
 13.2  Adverse Events to be Monitored in This Study ................................ ................................ .......................  45 
13.3  Duration of Adverse Event and Unanticipated Problem Monitoring and Recording  ...............................  47 
OUTCOMES TO BE ASSESSED  ................................ ................................ ................................ ............................  48 
14.1  Proportion of Donors who Discontinue Atorvastatin Because of Toxicity  ................................ ..............  48 
14.2  Acute GVHD  ................................ ................................ ................................ ................................ ...........  48 
14.3  Chronic GVHD  ................................ ................................ ................................ ................................ ........  48 
14.4  Recurrent Malignancy  ................................ ................................ ................................ .............................  48 
14.5  Non-relapse Mortality (NRM)  ................................ ................................ ................................ ..................  48 
14.6  Overall Survival (OS)  ................................ ................................ ................................ ..............................  48 
14.7  Proportion of Patients Requiring Secondary Systemic  Immunosuppressi ve Treatment  ........................  49 
DATA AND SAFETY MONITORING PLAN  ................................ ................................ ................................ .............  49 
15.1  Principal Investigator  ................................ ................................ ................................ ..............................  49 
15.2  Data Safety Monitoring Board (DSMB)  ................................ ................................ ................................ ... 49 
15.3  Trial Monitoring  ................................ ................................ ................................ ................................ ....... 50 
DATA MANAGEMENT AND PROTECTION OF CONFIDENTIALITY  ................................ ................................ .... 50 
STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ .........................  51 
17.1  Primary Endpoint and Sample Size  ................................ ................................ ................................ ........  51 
17.2  Secondary Endpoints  ................................ ................................ ................................ ..............................  52 
17.3  Mandatory Ad Hoc  DSMB Review  ................................ ................................ ................................ ..........  52 
17.4  Projected Ethnic and Gender Distribution  ................................ ................................ ..............................  53 
Ethnic Category  ................................ ................................ ................................ ................................ ........................  53 
Racial Categories  ................................ ................................ ................................ ................................ .....................  53 
TERMINATION OF STUDY  ................................ ................................ ................................ ................................ ..... 53 
REFERENCES  ................................ ................................ ................................ ................................ .........................  54 
TABLE OF APPENDICES  ................................ ................................ ................................ ................................ ........  55 
Serious Adverse Event Report  ................................ ................................ ................................ .............................  70 
Protocol 2546  ................................ ................................ ................................ ................................ .......................  70 
Notice of Death  ................................ ................................ ................................ ................................ .....................  71 
Comorbidities  ................................ ................................ ................................ ................................ ...........................  90 
2546.00  - Nonablative  
4 
FHCRC Current Version:  02/06/2018  
 
 ABBREVIATIONS  
 
AABB  American Association of Blood Banks  
ABW  actual body weight  
AE adverse event  
ALL acute lymphoblastic leukemia  
AML acute myeloid leukemia  
ALT alanine amino transferase  
AST aspartate amino transferase  
β-HCG  beta human chorion gonadotropin  
BMT  bone marrow transplantation  
BSA body surface area  
BU busulfan  
CAT computed axial tomography  
CCO  Clinical Coordinator Office  
CI confidence interval  
CML  chronic myeloid leukemia  
CMV  cytomegalovirus  
CNS  central nervous system  
CPK creatine phosphokinase  
CR complete remission  
CSP cyclosporine  
Css concentration at steady state  
CTCAE  common toxicity criteria for adverse events  
CTN Clinical Trials Network  
CXR  chest x -ray 
CY cyclophosphamide  
DFS disease -free survival  
DLCO  Diffusion capacity of lung —carbon monoxide  
DSMB  data and safety monitoring board  
DSMP  data and safety monitoring plan  
ECOG  Eastern Cooperative Oncology Group  
EKG  electrocardiogram  
EMG  electromyogram  
FACT  Foundation for the Accreditation of Cellular Therapy  
FEF forced expiratory flow  
FEV1  forced expiratory volume in 1 second  
FHCRC  Fred Hutchinson Cancer Research Center  
FLU fludarabine  
FVC forced vital capacity  
GCP  Good Clinical Practice  
GI gastrointestinal  
G-CSF granulocyte colony -stimulating factor  
GVHD  graft-versus -host disease  
GVL graft-versus -leukemia  
HCT hematopoietic cell transplantation  
HIV Human immunodeficiency virus  
HLA human leukocyte antigen  
HR hazard ratio  
2546.00  - Nonablative  
5 
FHCRC Current Version:  02/06/2018  
 
 HRPP  human research protection plan  
HTLV  human T cell lymphotropic virus  
IBW ideal body weight  
IRB institutional review board  
IRO  Institutional Review Office  
IST immunosuppressive treatment  
MDS  myelodysplastic syndrome  
MESNA  sodium -2-mercapto ethane sulfonate  
MMF  mycophenolate mofetil  
MTX  methotrexate  
MUGA  Multiple gated acquis ition 
NIH National Institutes of Health  
NCI National Cancer Institute  
NRM  non-relapse mortality  
OS overall survival  
OWL  optical web library  
PBSC  peripheral blood stem cell  
PCR  polymerase chain reaction  
PFT pulmonary function tests  
PI principal investigator  
RV residual volume  
SAE serious adverse event  
SCCA  Seattle Cancer Care Alliance  
TAC Tacrolimus  
TBI total body irradiation  
UPN  unique patient number  
URD  unrelated donor  
UW University of Washington  
  
2546.00  - Nonablative  
6 
FHCRC Current Version:  02/06/2018  
 
  
INTRODUCTION  
 
This document  is a clinical research protocol that will be conducted in compliance with Federal 
regulations and all applicable Institutional Review Board (IRB) requirements. This protocol 
builds on seminal observations from 2 previous studies.  
In two retrospective anal yses of outcomes among 1206 recipients of HLA -matched HCT [1,2],  
we found:  
▪ Statin  use by HLA -identical sibling donors  was associated with profound protection 
against severe acute GVHD. GVHD -protection was not offset by increased relapse 
rates.  
▪ Recipient  statin use beyond day 100 after transplant was associated with a reduced risk 
of chronic GVHD at the expense of an increased risk of relapse.  
▪ GVHD -protective effects were restricted to patients given CSP -based postgrafting 
immunosuppression and not observ ed among those given TAC.  
▪ GVHD -protective effects were most pronounced in the gastrointestinal tract.  
 
Based on the favorable outcomes associated with donor statin use in the retrospective 
analyses, the present study seeks to confirm these finding prospect ively. Specifically, we 
propose to treat HLA -identical related donors with atorvastatin for 2 weeks prior to collection of 
PBSC aimed at reducing the risk of severe acute GVHD in recipients after nonmyeloablative 
HCT.  
 
BACKGROUND  
 
2.1 Immunomodulatory effe cts of statins.  
In recent years, 3 -hydroxy -3-methylglutaryl coenzyme A (HMG -CoA) reductase inhibitors, or 
"statins", have been shown to alter immune function in ways that may contribute to their anti -
atherosclerotic effects. Statins also appear to reduce immune responses to autoantigens and 
alloantigens [3 -6]. The best characterized activity of statins involves inhibition of mevalonate 
and cholesterol biosynthesis, which is mediated by binding to HMG -CoA reductase. Blocking 
mevalonate production, ho wever, also inhibits the synthesis of intermediates required for 
isoprenylation of GTP -binding cell signaling proteins such as Ras, Rac and Rho, thereby 
disrupting intracellular signaling pathways  [6-9]. Immune functions shown t o be promoted by 
statins are Th2 -polarization1 and expansion of regulatory T cells (Treg ) [10]. At the same time 
statins inhibit lymphocyte trafficking to sites of inflammation [11 -13], antigen -presenting cell 
(APC) function [14,15 ], and the development of Th 17 cells [16]. While statin -mediated changes in 
immune function have been studied extensively, the potential immunosuppressive synergism 
between statins and calcineurin inhibitors has not been examined.  
 
2.2 Statins for GVHD -prevention: Preclinical and clini cal studies  
Zeiser et al. observed a significantly reduced mortality related to acute GVHD  when either donor 
or recipient mice were given  atorvastatin for 10 days before major histocompatibility complex 
(MHC) -mismatched allogeneic HCT [3].  This study also showed that statin -mediated protection 
against GVHD was due to parallel effects on T cells and APC, and that therapy did not simply 
2546.00  - Nonablative  
7 
FHCRC Current Version:  02/06/2018  
 
 Table 1: Multivariate analyses for association of recipient and donor statin use with various outcomes.*  
 All patients  
(n=567)  Patients with CSP -based GVHD -prophylaxis  
(n=417)  
(R+/D -, n=16)  (R-/D+, n=75)  (R+/D+, n=12)  (R+/D -, n=13)  (R-/D+, n=54)  (R+/D+, n=10)  
Endpoint  HR* 
(95% CI)  p* HR 
(95% CI)  p HR* 
(95% CI)  p* HR* 
(95% CI)  p* HR* 
(95% CI)  p* HR* 
(95% CI)  p* 
Grade  2-4 
GVHD  1.01 
(0.5-2.0) 0.98 0.89 
(0.6-1.2) 0.47 0.33 
(0.1-1.0) 0.06 1.10 
(0.5-2.3) 0.79 0.79  
(0.5-1.2) 0.23 0.22 
(0.1-0.9) 0.03 
Grade 3 -4 
GVHD  1.78 
(0.6-5.0) 0.28 0.28 
(0.1-0.9) 0.03 0.00 
(undef.)  0.06 1.76 
(0.6-5.0) 0.29 0.00 
 (undef)  <0.0001  0.00 
(undef.)  0.06 
Chronic 
GVHD  0.93 
(0.5-1.8) 0.83 0.82 
(0.6-1.2) 0.26 0.58 
(0.3-1.3) 0.19 0.79 
(0.4-1.6) 0.53 0.94 
 (0.6-1.4) 0.76 0.59 
(0.2-1.5) 0.25 
Relapse/ 
disease 
prog.  0.97 
(0.4-2.7) 0.96 0.63 
(0.4-1.1) 0.11 0.74 
(0.2-3.0) 0.67 1.27 
(0.4-3.6) 0.66 0.72 
 (0.4-1.3) 0.30 1.04 
(0.3-4.3) 0.95 
NRM  0.45 
(0.2-1.2) 0.12 0.72 
(0.4-1.2) 0.17 0.66 
(0.2-2.0) 0.49 0.36 
(0.1-1.1) 0.08 0.67 
 (0.4-1.2) 0.15 0.86 
(0.3-2.7) 0.80 
Overall 
mortality  0.58 
(0.3-1.2) 0.16 0.73 
(0.5-1.1) 0.10 0.77 
(0.3-1.9) 0.56 0.53 
(0.2-1.2) 0.14 0.75 
 (0.5-1.1) 0.18 1.00 
(0.4-2.5) 0.99 
Outcomes are shown for all patients (n=567; left table) and for patients with CSP-based GVHD -prophylaxis (n=417; right 
table). Outcome estimates are in comparison to controls where both donor and recipient did not receive statin treatment at 
the time of HCT (n=464 for “all patients” and n=340 for patients with CSP -based GVHD -prophylaxis).  *Adjusted for: Sex-
mismatch, conditioning intensity, donor age >50 years, patient age >50 years, and disease risk.  Abbreviations pertaining 
to statin treatment at the time of transplant : R-/D-: neither recipient nor donor; R+/D -, recipient only; R -/D+, donor only;  
R+/D+, both recipient and donor.    suppress T cell responses in general, as the ability of the transplanted T cells to kill tumor cells 
(GVT effect) was preser ved. 
In a recent retrospective analysis of 67 patients who received HLA -matched or mismatched 
related or unrelated allografts for treatment of hematologic malignancies, Hamadani et al. found 
a trend towards a decreased risk of grade 2 -4 acute GVHD (10% ver sus 40%; p=0.08) among 
the 10 recipients who were under treatment with a statin at the time of HCT, compared to those 
who were not  [17]. In this analysis, however, the authors did not account for donor statin 
exposure, and definitive conclusions were limit ed by small sample size and heterogeneity of the 
patient population.  
Most pertinent to the design of the present study was the observation that  donor statin use 
was associated with protection  against severe acute GVHD after HCT from HLA -identical 
related donors  [1]. In retrospective analysis (n=567), w e found that compared to allografts 
where neither the donor nor recipient used  a statin at the time of transplant (n=464), statin use 
by the donor and not the recipient (n=75) was associated with a profoundly decreased risk  of 
grade 3 -4 acute GVHD  (multivariate hazard ratio [HR], 0.28; 95% confidence i nterval [CI], 0.1 -
0.9; p=0.03) ( Table 1 ). Statin use by both donor and recipient (n=12) was suggestively 
associated with a decreased risk of grade 3 -4 acute GVHD (HR, 0.00; 95%  CI, undefined; 
p=0.06), while statin use by the recipient and not the donor (n=16) did not confer protection  
against acute GVHD. D onor statin -treatment was associated with significant protection against 
acute GVHD in the gastrointestinal tract (p=0.02) bu t not in the skin.  Surprisingly, statin -
associated GVHD -protection was re stricted to recipients with CSP-based postgrafting immu no-
suppression (n=417; 74% ; HR, 0.0; 95% CI, undefined ; p<0.0001)  and was not observed 
among those given TAC (significance of  effect modifi cation: CSP vs. TAC, p=0.009). The 
unexpected effect asso ciation between statins and CSP raises the question whether the two 
drugs share a cellular target that accounts for the observed immuno suppressive synergism.  
GVHD -protection associa ted with donor statin use was not offset by increased rates of recurrent 
malignancy . An increased risk of recurrent malignancy and a reduced risk of chronic GVHD 
were only  observed among recipients of HLA -matched related and unrelated grafts (n=1206) 
2546.00  - Nonablative  
8 
FHCRC Current Version:  02/06/2018  
 
 who were given statins beyond day 100 after transplant [2]. Overall, these results suggest that 
donor statin treatment (without recipient statin treatment ) may be a promising s trategy for 
preventing severe acute GVHD without compromising immunologic control of the underlying 
malignancy.  
The retrospective analysis also showed that favorable outcomes associated with donor statin 
use were not confined to a specific type of conditio ning intensity but seen after both 
nonmyeloablative and myeloablative HCT. Figure 1  shows the cumulative incidence of grade 3 -
4 acute GVHD among recipients of nonmyeloablative HCT from HLA -matched donors who has 
CSP-based immunosuppression according to don or statin use. This subgroup analysis shows 
that donor statin treatment has promise to substantially reduce the risk of severe acute GVHD 
and thereby NRM without compromising control of the underlying malignancy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3 Rationale for the Current Study  
 
Based on the favorable outcomes associated with donor statin use in the retrospective 
analyses, the present study seeks to confirm these finding prospectively. Specifically, we 
propose to treat HLA -identical related donors with atorvastatin during 2 weeks prior to collection 
of peripheral blood stem cells (PBSC) aimed at reducing the risk of severe acute GVHD in 
recipients. Since the statin -mediated GVHD -protecti ve effect was only seen among patients who 
had CSP -based immunosuppression and not among those given TAC, recipients enrolled in the 
present study will receive an immunosuppressive regimen that includes CSP. The study may be 
offered either as an independen t protocol that includes donor statin -treatment and the 
nonmyeloablative preparative regimen (low -dose TBI and fludarabine) or in conjunction with a 
designated separate transplant investigational protocol  that uses a nonmyeloablative 
preparative regimen, p rovided the respective transplant protocol does not use acute GVHD as 
the primary endpoint.  
 Figure 1:  Cumulative incidence of grade 3-4 acute GVHD  after 
nonmyeloablative hematopoietic cell transplantation  at the Fred Hutchinson 
Cancer Research Center (2001 -2007)  according to donor statin use. The 
analysis was restricted to patients who had CSP -based immunosuppression after 
transplant  (n=162) . 
 

2546.00  - Nonablative  
9 
FHCRC Current Version:  02/06/2018  
 
  
STUDY OBJECTIVES  
 
3.1 Primary Objective  
To assess whether 2 weeks of donor statin treatment reduces the risk of severe acute GVHD.  
 
3.2 Secondary Objective  
To ass ess whether 2 weeks of statin treatment of normal PBSC donors is feasible, tolerable and 
safe.  
 
STUDY DESIGN  
 
4.1 Description of Study  
This is a multi -center, single -arm, phase I I study, with plans to enroll a maximum of 100  
patients . This s tudy may be an adjunct to a non myeloablative protocol or treatment plan, or may 
be a primary treatment protocol.  For Outside Centers, it will be used as an adjunct only.  
 
4.2 Endpoints  
 
Primary Endpoint  
The primary endpoint is grade 3 -4 acute  GVHD  
 
Secondary Endpoin ts 
Secondary endpoints include the following  
o Grades II -IV acute GVHD  
o Proportion of patients requiring secondary systemic immunosuppressive 
therapy  
o Chronic extensive GVHD  
o Recurrent or progressive malignancy  
o Non-relapse mortality at 1 year  
o Overall survival  
o Proportion of donors  who have to discontinue atorvastatin because of 
toxicity  
 
 
PATIENT SELECTION  
 
5.1 Inclusion Criteria  (If Protocol 2546 serves as an adjunct protocol, the 
patient only needs to meet inclusion criteria 1 through 5A.)  
 
1) Availability of HLA-identical sibling donor  
2) Transplantation with PBSC  
3) CSP-based postgrafting immunosuppression  
2546.00  - Nonablative  
10 
FHCRC Current Version:  02/06/2018  
 
 4) Willingness to give informed consent  
5) A. Patient is enrolled on an investigational nonmyeloablative HCT protocol  or a 
nonmyeloablative treatment plan  with postgrafting CSP that does not use acute 
GVHD as its primary endpoint (protocol 2546 serves as adju nct protocol).  
or 
B. Patient is not enrolled on an investigational nonmyeloablative HCT protocol , in 
which  case protocol 2546 serves as an independent primary treatment protocol  and 
the patient must meet the following inclusion and exclusion criteria:  
  
a. Patients must have a hematologic malignancy treatable by nonmyeloablative 
HCT.   The following diseases will be permitted although other diagnoses can be 
considered if approved by PCC and the principal investigator:  
• Aggressive non -Hodgkin lymphomas (NHL) and other histologies s uch as 
diffuse large B -cell NHL  – not eligible for autologous HCT, not eligible for 
high-dose allogeneic HCT, or after failed autologous HCT.  
• Mantle -cell NHL  - may be treated in first CR. (Diagnostic LP required pre -
transplant)  
• Low grade NHL  – with <6 month duration of CR between courses of 
conventional therapy  
• CLL – must have either:  
i. failed to meet NCI Working Group criteria for complete or partial 
response a fter therapy with a regimen containing FLU (or another 
nucleoside analog) or experience disease relapse within 12 months 
after completing therapy with a regimen containing FLU (or another 
nucleoside analog);  
ii. failed FLU -CY-Rituximab (FCR) combination chemo therapy at any 
time point; or  
iii. have “17p deletion” cytogenetic abnormality. Patients should have 
received induction chemotherapy but could be transplanted in 1st CR;  
iv. Patients with a diagnosis of CLL (or small lymphocytic lymphoma) that 
progresses to proly mphocytic leukemia (PLL); or  
v. patients with T -cell CLL or PLL.  
• Hodgkin lymphoma  – must have received and failed frontline therapy.  
• Multiple myeloma  – must have received prior chemotherapy. Consolidation 
of chemotherapy by autografting prior to nonmyeloabla tive HCT is permitted.  
• Acute myeloid leukemia (AML)  – must have < 5% marrow blasts at the time 
of transplant.  
• Acute lymphocytic leukemia (ALL)  – must have <5% marrow blasts at the 
time of transplant.  
• Chronic myeloid leukemia (CML)  – Patients will be accept ed if they have 
shown intolerance to tyrosine kinase inhibitors  or are beyond CP1 and if 
they have received previous myelosuppressive chemotherapy or HCT, and 
have <5% marrow blasts at time of transplant.  
• Myelodysplasia (MDS)/ myeloproliferative syndrome ( MPS)  – Patients must 
have  <5% marrow blasts at time of transplant.   
• Waldenstrom’s macroglobulinemia  – must have failed 2 courses of therapy.  
 
2546.00  - Nonablative  
11 
FHCRC Current Version:  02/06/2018  
 
 b. Patients <12 years of age must be approved by the principal investigator and by 
a relevant patient review committe e, such as the FHCRC Patient Care 
Conference (PCC).  
c. Patients must have either relapsed after previous high -dose chemotherapy and 
autologous  or allogeneic  HCT, or else be ineligible for such an approach due to 
age, failure to mobilize suffi cient hematopoietic stem cells , medical comorbidities, 
or patient refusal (see d. below).  
d. Patients who refuse to be treated on a conventional autologous or allogeneic 
HCT protoc ol. 
 
5.2 Exclusion Criteria  (If Protocol 2546 serves as an adjunct protocol, the 
patient only needs to meet exclusion criteria 1 through 3.)  
 
1) Myeloablative preparative regimen . 
2) Participation in an investigational study that has acute GVHD as the primary endpoint . 
3) The allogeneic PBSC donor has a contraindication to statin treatment . 
4) Patients eligible for and willing to receive potentially curative high -dose chemotherapy 
and autologous HCT.  
5) Patients with the following levels of organ dysfunction are  ineligible:  
i. Cardiac : Cardiac ejection fraction <30% on MUGA scan or cardiac echo or active 
symptomatic coronary artery disease. Patients with cardiac disease should be 
evaluated with appropriate cardiac studies and/or cardiology consultation as 
clinically  indicated.  
ii. Pulmonary : DLCO corrected  <40% of predicted, TLC < 30% of predicted, FEV 1 <30% 
of predicted, or receiving continuous supplementary oxygen.  
iii. Hepatic : Patients with clinical or laboratory evidence of liver disease should be 
evaluated in conjunction  with the GI consult service for the cause of the liver 
disease, its clinical severity, and the degree of portal hypertension. Patients will 
be excluded if they are found to have fulminant liver failure, cirrhosis of the liver 
with evidence of portal hyper tension, bridging fibrosis, alcoholic hepatitis, 
esophageal varices, a history of bleeding esophageal varices, hepatic 
encephalopathy, refractory ascites related to portal hypertension, bacterial or 
fungal liver abscess, chronic viral hepatitis with total serum bilirubin >3mg/dl, or 
actively symptomatic biliary disease.  
iv. Renal : Patients with renal failure are eligible. However, patients with pre -existing 
renal insufficiency will likely have further compromise in renal function and may 
require dialysis.  
6) Patie nts who are seropositive for human immunodeficiency virus (HIV).  
7) Women who are pregnant or breast -feeding.  
8) Fertile men or women unwilling to use contraception during HCT and for 12 months 
afterward.  
9) Patients with active non -hematological malignancies (exce pt non -melanoma skin 
cancers) or those with non -hematological malignancies (except non -melanoma skin 
cancers) who have been rendered with no evidence of disease, but have a greater than 
20% chance of having disease recurrence within 5 years. This exclusion  does not apply 
to patients with non -hematologic malignancies that do not require therapy.  
10) Karnofsky score <60 for adult patients.  
11) Lansky -Play Performance Score <50 for pediatric patients.  
12) Patients with fungal pneumonia with radiological progression after receipt of 
amphotericin formulation or mold -active azoles for greater than 1 month.  
2546.00  - Nonablative  
12 
FHCRC Current Version:  02/06/2018  
 
 DONOR SELECTION   
 
6.1  Inclusions  
 
1) Age ≥ 18 years  
2) HLA genotypically identical sibling  
3) Willingness to give informed consent  
 
6.2 Exclusions  
 
1) Age < 18 years  
2) History of liver disease. A donor w ith a history of liver disease would be eligible if the 
serum ALT or AST are <2 times ULN.  
3) History of myopathy  
4) Hypersensitivity to atorvastatin  
5) Pregnancy  
6) Nursing mother  
7) Current serious systemic illness  
8) Concurrent tr eatment with strong inhibitors of hepatic CYP 3A4 (i.e. clarithromycin, 
erythromycin, protease inhibitors, azole antifungals)  
9) Failure to meet local criteria for stem cell donation  
10) Total creatinine kinase > 2 times the ULN  
 
 
INFORMED CONSENT OF SUBJECT AND DONOR  
 
Patients will be referred to the SCCA or appropriate outside center institution for consideration 
of a growth factor -mobilized blood cell transplant. Both patient and the related donor will be 
completely evaluated. The protocol will be discussed thoroughly  with patient , donor and family, 
and all known risks to patient and donor will be described. The procedure and alternative forms 
of therapy will be presented as objectively as possible and the risks and hazards of the 
procedure explaine d to the patient  and donor  or, in the case of minors,  to responsible family 
members. Consent will be obtained using forms approved by the local IRB. A summary of the 
conference will be dictated for the medical record detailing what was covered.  
 
PATIENT AN D DONOR REGISTRATION  
 
Eligible  FHCRC  donor/recipient pairs will be identified by the Clinical Coordinators Office (CCO) 
(Intake Office) and assigned UPNs (Unique Patient Numbers). The Data Management Office 
will register donors and recipients on to the pro tocol through the Data Management Office.   For 
patients enrolled at external sites, they will be registered to this study by FHCRC study staff.  
 
PLAN OF TREATMENT  
 
9.1 Donor Treatment with Atorvastatin   
 
• Eligible donors will be given atorvastatin (generic drug preferred, if available; otherwise 
Lipitor™)  40 mg/day orally starting on day -14. The last dose of atorvastatin will be 
2546.00  - Nonablative  
13 
FHCRC Current Version:  02/06/2018  
 
 administered in the morning of the last day of stem cell collection (total of 15 doses).  
• The following guidelines are to be follow ed if the day of transplant must be re -scheduled 
while the donor has already started atorvastatin treatment:  
o Transplant moved up : If the transplant date needs to be moved up by ≤ 3 days, a 
shortened atorvastatin treatment course is permissible provided at least 12 days 
of treatments (40 mg/day) can be given to the donor. If the transplant needs to be 
moved up for > 3 days, atorvastatin treatment of the donor will be discontinued 
and patients will not be followed with respect to the primary endpoint of this 
study.  
o Transplant delayed : If the transplant date needs to be delayed, an extended 
atorvastatin treatment course is permissible provided the new transplant date is 
already agreed upon and lies within 14 days from the date the decision to re -
schedule was made. If the re -schedule d transplant date lies beyond 14  days from 
the date the decision to re -schedule is made, the donor will discontinue 
atorvastatin treatment and resume statin treatment on d ay -14 before the new 
transplant date.  
 
9.2 Recipient Treatment  (References below to standard practice refer to 
standard practice at site where HCT is being performed.)  
 
• If the patient is enrolled on an investigational nonmyeloablative HCT protocol or a 
treatment plan that uses a nonmyeloablative preparative regimen with 
postgrafting CSP that does not use acute GVHD as its primary endpoint, the 
preparative regimen and immunosuppression after transplant will be according to  
respective protocol or treatment p lan (protocol 2546 serves as adjunct protocol).  
 
• If the patient is not enrolled on an investigational nonmyeloablative HCT 
protocol  or a treatment plan that uses a nonmyeloablative preparative 
regimen , protocol 2546 serves as an independent primary treatment 
protocol. The preparative regimen and immunosuppression after transplant 
will be as follows , see figure 2 : 
Treatment may be initiated in the outpatient department, and patients will be admitted to 
the hospital if medically necessary to address transplant -related complications or other 
medical issues.  
 
TBI Criteria for 2546 as a Primary Protocol:  
 
*Criteria for 3 Gy TBI (only for patients in Regimen A, Flu/TBI):  
Patients need to fulfill one or more of the following criteria for 3 Gy TBI:  
a) Patients with MDS, MPD, CML, or other hematologic malignancies not 
previously treated with myelosuppressive chemotherapy.  
b) Patients who had a previous allogeneic transplant.  
c) Patients who had a prior syngeneic transplant without subsequent 
myelosuppressive chemotherapy.  
d) Patients who have not had myelosuppressive chemotherapy within 3 -6 mo nths 
of HCT may be at higher risk of rejection depending on treatment history and 
underlying diagnosis. Confirm TBI dose (2 vs 3 Gy) with PI.  
2546.00  - Nonablative  
14 
FHCRC Current Version:  02/06/2018  
 
   
TBI Criteria for 2546 as an adjunct Protocol:  
 
*Criteria for 4 Gy TBI : 
Patients on Protocol 2546 as an adjunct pr otocol, TBI doses can exceed > 3 G y 
when the protocol serves as adjunct to a reduced intensity treatment plan that 
includes 4 Gy TBI . 
 
A. For 2546 as a Primary Protocol: Preparative Regimen and 
Postgrafting Immunosuppression  
 
a) Fludarabine 30 mg/m2/day IV on days -4, -3, and -2 (except for patients who 
had prior autologous HCT or equivalent high -dose therapy without HCT) within 
6 months.  
 b) Total body irradiation, 2 -3 Gy* ( 6-7 cGy/min; linear accelerator) , on day 0  
 c) Infusion of hematopoietic allograft on day 0  
 d) Post -grafting immunosuppression:  
i. CSP, 5 mg/kg PO q12 hrs from day -3 to day +56, then tapered to day 
+180   
 
Age < 6 years:  2 mg/kg IV  every 8 hours 
Age > 6 years:  2  mg/kg IV  every 12 hours  
 
ii. MMF, 15mg/kg PO /IV q12 hrs from day 0 to day +27  
 
Figure 2. Diagram of Treatment Plan  
 
 
 
 
 
 
 
 
 
 
 
 
 
            FLU:  30 mg/m2   on days -4, -3, -2 
 TBI: Single fraction (2 -3 cGy *) at 6 -7 cGy/min   
 
           MMF:       15 mg/kg p.o. q12 hrs days 0 to +27  
 
* See criteria for TBI dosing  
 
If T-Cell (CD3) chimerism is >50% on day +28 , then repeat only on days +84 and +365.* *If T-Cell (CD3)  
chimerism is 50% on day +28 , then repeat on days +56, +84, +180, & +365.   
 Granulocyte (CD33) chimerism on day +84 only.  
 Natural killer (NK) cell (CD56+) chimerism will be obtained on day 28.  
 Bone Marrow chimerism will be obtained on  days +84 & +365  Immunosuppression                      
 
  TBI 
HCT 
 Days                -4  -3 -2         0           14            28               56*                    84                   100                    180* Fludarabine  Chimerism  Chimerism  Chimerism  Evaluation  
MMF  
CSP 
 Regimen A: Flu/TBI  
   CSP:      5.0 mg/kg p.o. bid days -3 until day +56, taper to day +180  
       
 
2546.00  - Nonablative  
15 
FHCRC Current Version:  02/06/2018  
 
   (See Patient Post -Transplant Evaluation for more instructions and exceptions).  
 Treatment starts on Day -4 
  
 
 
 
 
 
 
 
 
 
 
 
 
             TBI: Single fraction (2 cGy) at 6 -7 cGy/min  
 
           MMF:       15 mg/kg p.o. q12 hrs days 0 to +27  
 
If T-Cell (CD3) chimerism is >50% on day +28 , then repeat only on days +84 and +365.*If T -Cell (CD3) chimerism is 
50% on day +28 , then repeat on days +56, +84, +180, & +365.   
 Granulocyte (CD33) chimerism on day +84 only.  
 Natural killer (NK) cell (CD56 +) chimerism will be obtained on day 28.  
 Bone Marrow chimerism will be obtained on days +84 & +365  
 (See Patient Post -Transplant Evaluation for more instructions and exceptions).  
Treatment starts on Day -3 
 
B. Peripheral Blood Stem Cell Infusion  
 
G-CSF-mobilized PBSC from an HLA -identical related donor will be the source of 
hematopoietic stem cells. Two 12 -liter leukaphereses on consecutive days, day -1 and 
day 0, will be obtained, and cells will be infused together on day 0 after TBI. Refer to 
institutional practice guidelines for methods of infusion. If the CD34+ cell dose is <5.0 x 
106/kg re cipient weight after the second collection, a third day collection should be 
added, with an extra dose of G -CSF given to the donor before the final collection.  
 
C. Adjustment of Post -grafting Immunosuppression  
 
Immunosuppression after transplant will be wi th MMF and CSP, as described above. 
CSP and MMF doses should be based on adjusted body weight. If actual weight is less 
than ideal weight, then actual body weight will be used. MMF will be initiated on day 0, 
with the first dose given 4 –6 hours after allog raft infusion is complete. In the absence of 
GVHD, CSP and MMF will be tapered and/or discontinued as described above. In the 
presence of GVHD, standard institutional recommendations for acute GVHD therapy 
should be followed. In the event of progression or  recurrence of malignancy, and in the 
absence of GVHD, CSP and MMF may be tapered more rapidly to stimulate a graft -vs.-
malignancy  effect, at the discretion of the attending physician. Investigational 
medications aimed at treating relapse or GVHD after tra nsplant are permissible.  
 
• Guidelines for CSP Administration and Monitoring  
If there is nausea and vomiting at anytime during CSP treatment, consideration  should 
be given  to administering CSP  intravenously at the appropriate dose that was used  to Immunosuppression                      
                          MMF  
                          CSP 
 
  
  
CSP 
  TBI 
HCT 
 Days                      -3            0           14            28               56*                    84                   100                    180* Chimerism  Chimerism  Chimerism  Evaluation  Regimen B: TBI Alone  
   CSP:      5.0 mg/kg p.o. bid days -3 until day +56, taper to day +180  
       
 
2546.00  - Nonablative  
16 
FHCRC Current Version:  02/06/2018  
 
 obtain a therapeutic level.  For pediatric patients, it is recommended that CSP dosing be 
initiated using the IV formulation and then converted to PO when tolerated .  The 
appropriate dose conversion fr om PO to IV  and IV to PO  should be discussed with the 
transplant pharmacist. Blood pressure, renal function and electrolytes (including 
magnesium) should be followed at least 3 times per week during the first month, twice 
weekly until day +100, then once p er week until CSP is stopped.  
 
CSP Dose Adjustments:  Initial high Cyclosporine (CSP) doses are required based on the 
preclinical nonmyeloablative canine studies, which used an equivalent dose to establish 
an allograft.  After day +28, CSP levels typical fo r unrelated HCT will be targeted.  Dose 
reduction should only be made if CSP toxicity is present, and/or levels exceed values 
provided in Table 2. There are two methods for calculating CSP levels.  Table 2 provides 
desired levels for specific methods.  To avoid inadequate immune suppression, dose 
reductions should be conservative.  Therapeutic levels of CSP should be maintained.  
 
 
 Table 2:  CSP Dose Adjustment  
 
 CSP Level to Target 
Using LC -MS/MS 
Method  CSP Level to Target 
Using Immunoassay 
Method  
Day “0” – Day +28  
Whole blood “trough” (11 -12 hrs 
from prior dose)   
400 ng/ml   
500 ng/ml  
(upper end therapeutic 
range for this method)  
 
After Day +28  
  
120 - 360 ng/ml  
  
150 - 450 ng/ml  
 
Levels >480 ng/ml by LC -MS/MS 
Method  
• with or without CSP toxicity  
• decrease GFR >50% 
• increase creatinine 2x 
baseline due to CSP  
  
 
 
25% dose reduction   
 
 
N/A 
Levels >600 ng/ml by Immunoassay 
Method  
• with or without CSP toxicity  
• Decrease GFR >50% 
• increase creatinine 2x 
baseline due to CSP   
 
N/A  
 
25% dose reduction  
Patients on Hemodialysis  320 ng/ml  400 ng/ml  
 
• Guidelines for MMF Administration and Monitoring  
If there is nausea or vomiting at any time preventing the oral administration of MMF, the 
drug should be administered intravenously. It will be left to the discretion of the pediatric 
2546.00  - Nonablative  
17 
FHCRC Current Version:  02/06/2018  
 
 attending wh ether  to initiate MMF dosing IV or PO.  The PO to IV  or IV t o PO  dose 
conversion should be discussed with the transplant pharmacist. If clinical judgment 
suggests observed toxicities are related to MMF, the dose may be adjusted. The 
adjustment or discontinuation of MMF at any point should be discussed with the PI a nd 
documented in the permanent medical record and all Case Report Forms (CRF).  
 
D.  Collection of Donor PBSC  
 
• G-CSF Administration to Donors:  
G-CSF will be administered by subcutaneous daily injections from day -4 to day 0 at a 
dose of 16 µg/kg/day  for 5 consecutive days. The schedule of G -CSF administration and 
PBSC collections should be confirmed with the personnel in the apheresis room. Day 0  
should be scheduled  on a Tuesday -Thursday, if possible  (FHCRC patients only) .  
 
 
 
• PBSC Collection:  
Donors will preferably undergo vein -to-vein collections, or may receive an appropriate 
catheter inserted on or before the day of apheresis. PBSCs will be co llected on the 
afternoon of day -1 and stored in the refrigerator at 4ºC overnight. A second collection 
will be performed the following afternoon and both collections will be infused on day 0. If 
<5x106 CD34+ cells/kg recipient weight are collected, an add itional (third) day of 
collection should be performed. If PBSC cannot be collected by a vein -to-vein technique, 
a percutaneous Mahurkar catheter will be inserted. General procedures will include the 
use of a standard apheresis machine (COBE Spectra, Lakewo od Colo.), and processing 
up to 16 liters of whole blood during the collection.  
 
Table 3:  Treatment Schema for HLA -Identical Related Donors  
 
Days   -4  -3  -2 -1  0 
G-CSF 16 
g/kg/SQ    X   X   X X  X 
G-PBMC 
collection     X  X 
 
Immunophenotyping of the G-PBMC  product will be performed by the cryobiology 
laboratory and will include T -cells and their subsets, monocytes, and NK cells.  
 
 
E. ABO -Incompatibility  
All patients with ABO incompatibility should be evaluated and treated acco rding to 
institutional standard practice.  
 
 
2546.00  - Nonablative  
18 
FHCRC Current Version:  02/06/2018  
 
 F. Post -transplant Growth Factors  
In general, patients should not receive post -transplant growth factors during the first 3 
weeks after transplant. Growth factors should not be given unless neutropenia (ANC 
<500/ μL) persists past day +21 after transplant.  
 
 
G. Infection Prophylaxis  
Patients will receive monitoring for and prophylaxis against viral, bacterial, and fungal 
infections per institutional standard practice.  
 
 
H. Evaluation of Chimerism  
 
Definitions:  For the purposes of this protocol, the following definitions will apply:   
For the purposes of this protocol, mixed chimerism  will be defined as the detection of 
donor T cells (CD3+) and granulocytes (CD 33+), as a proportion of the total T ce ll and 
granulocyte population, respectively, of greater than 5% and less than 95% in the 
peripheral blood. Full donor chimerism is defined as > 95% donor CD3+ T cells. Mixed 
or full donor chimerism will be evidence of donor engraftment. Increasing donor 
chimerism  is defined as an absolute increase of 20% of CD3+ T cells over the previous 
chimerism evaluation. Decreasing donor chimerism  is defined as an absolute decrease 
of 20% of CD3+ T cell chimerism over the previous month. Low donor chimerism is 
defined as < 40% CD3+ T cells after HCT. Low donor chimerism should always be 
confirmed with repeat peripheral blood T cell and granulocyte chimerism analysis.   A 
DNA -based assay that compares the profile of amplified fragment length polymorphisms 
(ampFLP) (or FIS H studies or VNTR) of the patient and donor will be used to quantitate 
chimerism of sorted peripheral blood T -cells (CD3+) and granulocytes (CD 33+). The 
same assay should be used in a given patient for repeated studies of chimerism.  This 
DNA -based analys is will also be performed on the whole nucleated cell fraction from 
marrow aspirates. Therapeutic decisions (i.e. DLI) will be made based on the results of 
sorted T -cell studies of peripheral blood.  For the purposes of this protocol, rejection  is 
defined a s the inability to detect or loss of detection of greater than 5% donor T cells 
(CD3+) as a proportion of the total T cell population, respectively, after nonmyeloablative 
HCT. Also for the purposes of this protocol, graft failure  is defined as grade IV 
thrombocytopenia and neutropenia after day 21 that lasts > 2 weeks and is refractory to 
growth factor support.   
Bone marrow chimerism (unfractionated cells) will be evaluated at day +84 and one year 
after transplant. In peripheral blood, CD3 chimerism will b e evaluated on days +28, +84 
and one year after transplant; CD33 chimerism will be evaluated on day +84; CD56 
chimerism will be evaluated on day +28. Unless clinically indicated (i.e. poor previous 
chimerism, immunotherapy, hematopoietic insufficiency etc. ), further chimerism studies 
will not be performed.  
 
I. Continuation of immunosuppression .  
In the setting of low donor chimerism, immunosuppression may be continued or 
reinitiated at full dose so that DLI can be administered on a separate protocol. If there is 
disease progression in the setting of low donor chimerism, the algorithm for disease 
progression ( below ) should be followed. Patients who reject their graft may be eligible for 
a second allogeneic transplant on other protocols.  
2546.00  - Nonablative  
19 
FHCRC Current Version:  02/06/2018  
 
  
J. Discontinuation  of immunosuppression.  
Immunosuppression should be discontinued as per protocol unless the patient develops 
GVHD, has falling donor chimerism or has progressive or substantial persistent disease 
(see below ). In the setting of GVHD, CSP and MMF may be cont inued. GVHD at any 
time should be treated as per standard practice.  
 
K. Disease progression or persistence and mixed chimerism.  
Evidence of substantial persistent disease at day 80 or beyond may be an indication for 
therapeutic intervention while disease progression, at any time point will always be an 
indication for therapeutic intervention. Intervention for persistent disease at day 80 or 
beyond should be discussed with the Principal Investigator and the guideline below for 
progressive disease should be followed. If the attending physician believes that the 
patient requires very aggressive therapy for rapidly progressive disease, the case will be 
presented at the Patient Care Conference  (FHCRC patients only) . Otherwise, priority 
should be given to rapid r eduction of immunosuppression, option (a) below. Therapeutic 
options include:  
 
a. Discontinuation of immunosuppression. This should be considered the first 
therapeutic maneuver. If there is no GVHD, MMF should be stopped and CSP 
should be tapered over 2 weeks. Bone marrow aspirate and blood chimerism 
studies will be performed 2 weeks after discontinuation of immunosuppressi on. If 
there is no response to withdrawal of immunosuppression, < 20% increase in 
donor chimerism and there is no GVHD, patients will be considered as treatment 
failures. DLI will not be offered for disease progression or relapse on this 
protocol. In this situation, patients may receive further therapy as per institutional 
protocols for disease relapse or progression after allogeneic HCT. If no GVHD 
occurs, patients with progressive disease may be offered enrollment in other 
institutional protocols for DLI treatment. If there is >20% absolute increase in 
donor chimerism, patients should be observed for additional 2 weeks and 
chimerism studies then repeated. If there is progressive disease that requires 
therapy before 4 weeks or progressive disease occurs des pite onset of GVHD, 
patients can be treated off protocol with DLI or be considered for options (b) or 
(c) below.  
b. Intercurrent treatment with chemotherapy or radiation . Conventional 
chemotherapy or radiation therapy should be considered in the setting of  life-
threatening progression of malignancy. Patients in this situation would be 
considered treatment failures. After cytoreductive therapy is completed, 
chimerism should be evaluated and the administration of DLI off protocol 
considered.  
c. High -dose allo geneic HCT This option should be discussed with the principal 
investigator. Patients who undergo high -dose allogeneic HCT will be removed 
from the protocol at that time.  
d. CML or Ph (+) ALL patients with Persistent or Increased Minimal 
Residual Disease: At day +84 or beyond, if the patient has persistent or 
increased  MRD disease, dose -escalation of BCR/ABL tyrosine kinase inhibitor 
therapy or  DLI should be considered  
e. CML and PH (+) ALL patients with Relapse and Disease Progression:  
2546.00  - Nonablative  
20 
FHCRC Current Version:  02/06/2018  
 
 See above sections f or withdrawal of immunosuppression. If there is no response 
to withdrawal of immunosuppression and no GVHD has developed, dose 
escalation of BCR/ABL tyrosine -kinase inhibitor therapy and or DLI should be 
considered.  
 
L.  Assessment of Disease Responses  
The initial anti -tumor effect of allogeneic HCT will be evaluated with the intermittent 
analysis of appropriate tumor markers, if available: Responses will be classified as 
complete, partial response or no response. Response criteria for MM, NHL, CLL, CML, 
ALL, AML and MDS to be used in this study are described in Appendix E. Standard 
response criteria specific to other diseases will be used in assessing disease response 
for other patients on study.  
 
 
 
EVALUATION OF PATIENTS  
 
10.1 Patient Pre-transplant Evaluation for All Diseases  
 
1. History: A complete history with full details of the patient’s prior treatment and response.  
2. Careful physical exam with documentation of Karnofsky or Lansky score, HCT -CI score and 
findings related to under lying malignancy.  
3. Standard CBC with differential & platelets, comprehensive metabolic panel, magnesium, uric 
acid, ABO/Rh typing, hepatitis screen, CMV and toxoplasmosis serology, anti -HIV serology, and 
serum LDH.  
4. Pulmonary function tests with correc ted DLCO.  
5. CXR (PA and LAT).  
6. ECHO or MUGA for patients > 50 years of age, or history of cardiac disease or anthracycline 
exposure.  
7. Evaluation and prophylaxis of CNS disease  as per local practice guidelines.  
 
Immunophenotyping of the PBSC graft.  
Immunophenotyping of the PBSC product will be performed by the Cellular Therapy Laboratory 
and will include CD34, CD3/4 and CD3/8 cells. The residual specimen will be sent to the 
Heimfeld lab for phenotypic characterization of cellular subsets.   For patients enrolled at 
external sites, immunophenotyping will be performed at the local site.  
 
 
Additionally, see the following tables (Tables 4, 5, 6 and 7) for disease specific pre -
transplant evaluation  
 
 
2546.00  - Nonablative  
21 
FHCRC Current Version:  02/06/2018  
 
 Table 4: Disease -Specific Pre-Transplant Evaluations  for ALL and  CML  
 
Note: All bone marrow aspirates and biopsies are unilateral  and must be collected within 21 
days of treatment .  See Tables  8 and 10 for post -transplant evaluations and additional lab 
instructions  
 
Specimen / Test / Imaging  Clinical / 
Research  Comment  
Bone marrow aspirate  
 Pathology  Clinical   
Flow Cytometry  Clinical   
Cytogenetics  Clinical   
FISH for clonal abnormalities  Clinical  *If previously abnormal  
PCR for bcr/abl, p.210 breakpoint - *see comment  Clinical  *CML only   
PCR for bcr/abl, p.190 and p.210 breakpoints  - *see 
comment   Clinical  *Ph (+) ALL only  
 
Bone marrow biopsy  
 Pathology - *see comment  Clinical  *CML only  
2546.00  - Nonablative  
22 
FHCRC Current Version:  02/06/2018  
 
 Table 5: Disease -Specific Pre-Transplant Evaluations  for AML and MDS/MPD  
  
Note: All bone marrow aspirates and biopsies are unilateral  and must be collected within 21 
days  of treatment.   See Tables  8 and 10 for post -transplant evaluations and additional lab 
instructions  
  
Specimen / Test / Imaging  Clinical / 
Research  Comment  
Bone marrow aspirate  
 Pathology  Clinical   
Flow Cytometry  Clinical   
Cytogenetics  Clinical   
FISH for clonal abnormalities  Clinical  *If previously abnormal  
Bone marrow biopsy  
 Pathology - *see comment  Clinical  *MDS/MPD only  
 
2546.00  - Nonablative  
23 
FHCRC Current Version:  02/06/2018  
 
 Table 6: Disease -Specific Pre-Transplant Evaluations  for CLL, HL, NHL  
 
Note: All bone marrow aspirates and biopsies are bilateral  and must be collected within 30 
days  of treatment.   See Tables  8 and 10 for post -transplant evaluations and additional lab 
instructions . If disease status can be determined pre -allo without all specific tests, the tests may 
be omitted.   
 
 
Specimen / Test / Imaging  Clinical / 
Research  Comment  
Bone marrow aspirate  
 Pathology  Clinical   
Flow Cytometry - *see comment  Clinical  *No HL  
Cytogenetics  Clinical   
FISH for clonal abnormalities  Clinical  *If previously abnormal  
PCR for t(11:14)  - *see comment  Clinical  *Mantle Cell NHL only  
PCR for t(14:18)  - *see comment  Clinical  *Follicular NHL only  
Bone marrow biopsy  
 Pathology - *see comment  Clinical  *HL – only if history of BM 
involvement  
Peripheral Blood  
 Quantitative Ig levels  Clinical   
β-2 microglobulin  Clinical   
LDH  Clinical   
ZAP – 70 by flow cytometry - *see comment  Clinical  *CLL only – for patients not in CR  
Imaging  
 CT of chest, abdomen, pelvis (neck if indicated)  Clinical   
 
2546.00  - Nonablative  
24 
FHCRC Current Version:  02/06/2018  
 
 Table 7: Disease -Specific Pre-Transplant Evaluations  for MM and Waldenstrom’s 
Macroglobulinemia  
 
Note: All bone marrow aspirates and biopsies are bilateral  and must be collected within 30 
days  of treatment.   See Tables  8 and 10 for post -transplant evaluations and additional lab 
instructions . If disease status can be determined pre -allo without all specific tests, the tests may 
be omitted.    
 
 
Specimen / Test / Imaging  Clinical / 
Research  Comment  
Bone marrow aspirate  
 Pathology  Clinical   
Flow Cytometry  Clinical   
Cytogenetics  Clinical   
FISH for clonal abnormalities  Clinical  *If previously abnormal  
Bone marrow biopsy  
 Pathology  Clinical   
Peripheral Blood  
 SPEP/IFIX  Clinical   
Quantitative Ig levels  Clinical   
β-2 microglobulin  Clinical   
Cryoglobulins, c -reactive protein, serum 
viscosity - *see comment  Clinical  *Serum viscosity only for patients with 
>3gm/dL IgM monoclonal protein or 
>4gm/dL IgA or IgG protein  
Urine  
 UPEP/IFIX  Clinical   
Protein / creatinine clearance  Clinical   
Imaging  
 MRI –  *see comment  Clinical  *MM only  
Skeletal survey –  *see comment  Clinical  *MM only  
CT of chest, abdomen, pelvis (neck if 
indicated)  –  *see comment  Clinical  *Waldenstrom’s Macroglobulinemia 
only 
  
2546.00  - Nonablative  
25 
FHCRC Current Version:  02/06/2018  
 
 10.2 Patient Post -transplant Evaluation  
 
See Standard Practice Manual for standard treatment guidelines (Allo ) during conditioning, post-
transplant inpatient a dmission and  during f irst 100 days after initial hospital discharge.  See 
Table 8 for disease specific post -transplant eva luation on Day +28, 56, 84, etc; t his is a 
recommended evaluation schedule.  
 
See Standard Practice Manual for Evaluation Guidelines After Departure from FHCRC System.  
 
For patients enrolled at external sites, post -transplant evaluations will be performed per local 
standard practice.  The testing listed in Table 8 are recommended evaluations.  All testing will  
be performed at the local institution.  
 
Guidelines for bone ma rrow evaluations beyond one year after transplant:  
1) Marrow evaluations represent the standard of care for all patients at the one -year LTFU 
visit after HCT.  
 
2) Subsequent marrow evaluations also represent the standard of care if…  
a. The CBC or platelet count sho ws any abnormalities  
b. If there is any clinical indication  for the procedure, OR  
c. If the most recent marrow evaluation or other testing showed any evidence of 
persistent malignancy, OR  
d. If the patient has a disease for which a low -dose maintenance treatment w ould 
be indicated if disease were discovered after a previous evaluation with no 
evidence of malignant cells.   
 
 
 
2546.00  - Nonablative  
26 
FHCRC Current Version:  02/06/2018  
 
 Table 8: Post -Transplant Evaluation  
This is a recommended evaluation schedule.  
See Tables 4 - 7 for pre -transplant evaluations.   Additional lab instructions in Table 9. 
 
Disease  Specimen/ Test/ Imaging  Clinical/ 
Research  Comment  Days  Years  Annual x 
5 years  28 56 84 180 1 1.5 
Ph (-) ALL  BM aspirate * If CR documented at one year, and there is recovery of normal blood counts, bone marrow after one year may be obtained based on clinical jud gment 
 Chimerism  Clinical     x  x   
Pathology  Clinical   x x x x x x x 
Flow cytometry  Clinical   x x x x x x x 
Cytogenetics  Clinical  *If abnormal pre -transplant  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
FISH for clonal 
abnormalities  Clinical  *If abnormal pre -transplant  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
Peripheral blood  
 Chimerism (CD3+)  Clinical  *Days 56 and 180 only if 
<50% on day 28  x *See 
comment  x *See 
comment  x   
Chimerism (CD33+)  Clinical     x     
Chimerism  (NK CD56+)  Clinical   x       
GVHD evaluation  Clinical  See text for details    x     
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
2546.00  - Nonablative  
27 
FHCRC Current Version:  02/06/2018  
 
 Disease  Specimen/ Test/ Imaging  Clinical/ 
Research  Comment  Days  Years  Annual x 
5 years  28 56 84 180 1 1.5 
Ph (+) ALL  
 BM aspirate * If CR documented at one year, and there is recovery of normal blood counts, bone marrow after one year may be obtained based on clinical judgm ent 
 Chimerism  Clinical     x  x   
Pathology  Clinical   x x x x x x x 
Flow cytometry  Clinical   x x x x x x x 
Cytogenetics  Clinical   x x x x x x x 
FISH for  bcr/abl and other 
clonal abnormalities  Clinical   x x x x x x x 
Peripheral blood  
 Chimerism (CD3+)  Clinical  *Days 56 and 180 only if 
<50% on day 28  x *See 
comment  x *See 
comment  x   
Chimerism (CD33+)  Clinical     x     
Chimerism  (NK CD56+)  Clinical  Optional for outside 
institutions  x       
PCR for bcr -abl, p.190 and 
p.210 breakpoints  Clinical  * p.190 and p.210 only if 
present in pre -transplant 
marrow  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
GVHD evaluation  Clinical  See text for details    x     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
        
2546.00  - Nonablative  
28 
FHCRC Current Version:  02/06/2018  
 
 Disease  Specimen/ Test/ Imaging  Clinical/ 
Research  Comment  Days  Years  Annual x 
5 years  28 56 84 180 1 1.5 
AML  BM aspirate * If CR documented at one year, and there is recovery of normal blood counts, bone marrow after one year may be obtained based on clinical judgm ent 
 Chimerism  Clinical     x  x   
Pathology  Clinical   x x x x x x x 
Flow cytometry  Clinical   x x x x x x x 
Cytogenetics  Clinical  *If abnormal pre -transplant  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
FISH for clonal 
abnormalities  Clinical  *If abnormal pre -transplant  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
Peripheral blood  
 Chimerism (CD3+)  Clinical  *Days 56 and 180 only if 
<50% on day 28  x *See 
comment  x *See 
comment  x   
Chimerism (CD33+)  Clinical     x     
Chimerism  (NK CD56+)  Clinical  Optional for outside 
institutions  x       
GVHD evaluation  Clinical  See text for details    x     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
2546.00  - Nonablative  
29 
FHCRC Current Version:  02/06/2018  
 
 Disease  Specimen/ Test/ Imaging  Clinical/ 
Research  Comment  Days  Years  Annual x 
5 years  28 56 84 180 1 1.5 
MDS/ MPD  
 
 BM aspirate *see biopsy  
                    ** If CR documented at one year, and there is recovery of normal blood counts, bone marrow after one year may be obtained based on clinical judgm ent 
 Chimerism  Clinical     x  x   
Pathology  Clinical   x x x x x x x 
Flow cytometry  Clinical   x x x x x x x 
Cytogenetics  Clinical  *If abnormal  pre -transplant  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
FISH for clonal 
abnormalities  Clinical  *If abnormal  pre-transplant  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
BM biopsy  
 Pathology  Clinical  *For pts. with evidence or 
history of myelofibrosis  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
Peripheral blood  
 Chimerism (CD3+)  Clinical  *Days 56 and 180 only if 
<50% on day 28  x *See 
comment  x *See 
comment  x   
Chimerism (CD33+)  Clinical     x     
Chimerism  (NK CD56+)  Clinical  Optional for outside 
institutions  x       
GVHD evaluation  Clinical  See text for details    x     
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
          
2546.00  - Nonablative  
30 
FHCRC Current Version:  02/06/2018  
 
 Disease  Specimen/ Test/ Imaging  Clinical/ 
Research  Comment  Days  Years  Annual x 
5 years  28 56 84 180 1 1.5 
CML  BM aspirate *see biopsy  
                       ** If CR documented at one year, and there is recovery of normal blood counts, bone marrow after one year may be obtained based on cli nical judg ment 
 Chimerism  Clinical     x  x   
Pathology  Clinical   x x x x x x x 
Flow cytometry  Clinical   x x x x x x x 
Cytogenetics  Clinical   x x x x x x x 
FISH for bcr -abl and 
other clonal 
abnormalities  Clinical   x x x x x x x 
BM biopsy  
 Pathology  Clinical  *If abnormal pre -transplant    *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
Peripheral blood  
 Chimerism (CD3+)  Clinical  *Days 56 and 180 only if 
<50% on day 28  x *See 
comment  x *See 
comment  x   
Chimerism (CD33+)  Clinical     x     
Chimerism  (NK 
CD56+)  Clinical  Optional for outside 
institutions  x       
PCR for bcr -abl, and 
p.210 breakpoint  Clinical  *p.190 and p.210 only if 
present in pre-transplant 
marrow  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
GVHD evaluation  Clinical  See text for details    x     
 
 
 
 
 
 
 
 
            
2546.00  - Nonablative  
31 
FHCRC Current Version:  02/06/2018  
 
 Disease  Specimen/ Test/ Imaging  Clinical/ 
Research  Comment  Days  Years  Annual x 
5 years  28 56 84 180 1 1.5 
CLL  
 BM aspirate *see biopsy  
                       ** If CR documented at one year, and there is recovery of normal blood counts, bone marrow after one year may be obtained based on cli nical judg ment 
 Chimerism  Clinical     x  x   
Pathology  Clinical   x x x x x x x 
Flow cytometry  Clinical   x x x x x x x 
Cytogenetics  Clinical  *If abnormal pre -transplant  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
FISH for clonal 
abnormalities  Clinical  *If abnormal pre-transplant  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
BM biopsy  
 Pathology  Clinical     x x x x x 
Peripheral blood  
 Chimerism (CD3+)  Clinical  *Days 56 and 180 only if 
<50% on day 28  x *See 
comment  x *See 
comment  x   
Chimerism (CD33+)  Clinical     x     
Chimerism  (NK CD56+)  Clinical  Optional for outside 
institutions  x       
Flow cytometry  Clinical  * If peripheral blood 
involvement pre -transplant 
AND bone marrow not done  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
Quantitative Ig levels  Clinical  *If abnormal pre -transplant    *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
LDH  Clinical    x x x x x x 
Imaging  
 CT chest, abdomen, pelvis  
(neck if indicated)  Clinical  *Day 56 only if abnormal  pre -
transplant   *See 
comment  x x x x x 
GVHD evaluation  Clinical  See text for details    x     
 
 
 
 
 
 
  
2546.00  - Nonablative  
32 
FHCRC Current Version:  02/06/2018  
 
 Disease  Specimen/ Test/ Imaging  Clinical/ 
Research  Comment  Days  Years  Annual x 
5 years  28 56 84 180 1 1.5 
HL - 
No history of 
BM 
involvement  BM aspirate * If CR documented at one year, and there is recovery of normal blood counts, bone marrow after one year may be obtained based on cli nical judg ment 
 Chimerism  Clinical     x  x   
Pathology  Clinical     x  x   
Cytogenetics  Clinical  *If abnormal pre -transplant    *See 
comment   *See 
comment    
FISH for clonal 
abnormalities  Clinical  *If abnormal pre -transplant    *See 
comment   *See 
comment    
Peripheral blood  
 Chimerism (CD3+)  Clinical  *Days 56 and 180 only if 
<50% on day 28  x *See 
comment  x *See 
comment  x   
Chimerism (CD33+)  Clinical     x     
Chimerism  (NK CD56+)  Clinical  Optional for outside 
institutions  x       
LDH  Clinical    x x x x x x 
Imaging  
 CT chest, abdomen, pelvis  
(neck if indicated)  Clinical  *Day 56 only if abnormal  pre -
transplant   *See 
comment   x x x x x 
GVHD evaluation  Clinical  See text for details    x     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
2546.00  - Nonablative  
33 
FHCRC Current Version:  02/06/2018  
 
 Disease  Specimen/ Test/ Imaging  Clinical/ 
Research  Comment  Days  Years  Annual x 
5 years  28 56 84 180 1 1.5 
HL - 
History of BM 
involvement  BM aspirate *see biopsy  
                       ** If CR documented at one year, and there is recovery of normal blood counts, bone marrow after one year may be obtained based on cli nical judg ment 
 Chimerism  Clinical     x  x   
Pathology  Clinical   x x x x x x x 
Cytogenetics  Clinical  *If abnormal pre -transplant  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
FISH for clonal 
abnormalities  Clinical  *If abnormal pre -transplant  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
BM biopsy  
 Pathology  Clinical     x x x x x 
Peripheral blood  
 Chimerism (CD3+)  Clinical  *Days 56 and 180 only if 
<50% on day 28  x *See 
comment  x *See 
comment  x   
Chimerism (CD33+)  Clinical     x     
Chimerism  (NK CD56+)  Clinical  Optional for outside 
institutions  x       
LDH  Clinical    x x x x x x 
Imaging  
 CT chest, abdomen, pelvis  
(neck if indicated)  Clinical  *Day 56 only if abnormal  pre -
transplant   *See 
comment   x x x x x 
GVHD evaluation  Clinical  See text for details    x     
 
 
 
 
 
 
 
 
 
 
 
 
2546.00  - Nonablative  
34 
FHCRC Current Version:  02/06/2018  
 
 Disease  Specimen/ Test/ Imaging  Clinical/ 
Research  Comment  Days  Years  Annual x 
5 years  28 56 84 180 1 1.5 
NHL – 
No History of 
BM 
involvement  
 
*see separate 
section for 
additional PCR 
on Mantle Cell 
and Follicular 
NHLs in 
suspected CR  
 
 
 
 
 
 
 
 
 
 BM aspirate *  If CR documented at one year, and there is recovery of normal blood counts, bone marrow after one year may be obtained based on clinical judg ment 
 Chimerism  Clinical     x  x   
 Pathology  Clinical     x  x   
 Flow cytometry  Clinical     x  x   
 Cytogenetics  Clinical  *If abnormal pre -transplant    *See 
comment   *See 
comment    
Peripheral blood  
 Chimerism (CD3+)  Clinical  *Days 56 and 180 only if 
<50% on day 28  x *See 
comment  x *See 
comment  x   
 Chimerism (CD33+)  Clinical     x     
 Chimerism  (NK CD56+)  Clinical  Optional for outside 
institutions  x       
 Flow cytometry  Clinical  * If peripheral blood 
involvement pre -transplant, if 
bone marrow not obtained  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
 β-2 microglobulin  Clinical     x     
 LDH  Clinical     x x x x x 
Imaging  
 CT chest, abdomen, pelvis 
(neck if indicated)  Clinical  *Day 56 only if abnormal  pre -
transplant   *See 
comment   x x x x x 
GVHD evaluation  Clinical  See text for details    x     
 
 
 
 
 
  
2546.00  - Nonablative  
35 
FHCRC Current Version:  02/06/2018  
 
 Disease  Specimen/ Test/ Imaging  Clinical/ 
Research  Comment  Days  Years  Annual x 
5 years  28 56 84 180 1 1.5 
NHL – 
History of BM 
involvement  
 
*see separate 
section for 
additional PCR 
on Mantle Cell 
and Follicular 
NHLs in 
suspected CR  
 BM aspirate *see biopsy  
** ** If CR documented at one year, and there is recovery of normal blood counts, bone marrow after one year may be obtained based on cli nical judg ment 
 Chimerism  Clinical     x  x   
Pathology  Clinical   x x x x x x x 
Flow cytometry  Clinical   x x x x x x x 
Cytogenetics  Clinical  *If abnormal pre -transplant  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
FISH for clonal 
abnormalities  Clinical  *If abnormal pre -transplant  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
BM biopsy  
 Pathology  Clinical     x x x x x 
Peripheral blood  
 Chimerism (CD3+)  Clinical  *Days 56 and 180 only if 
<50% on day 28  x *See 
comment  x *See 
comment  x   
Chimerism (CD33+)  Clinical     x     
Chimerism  (NK CD56+)  Clinical  Optional for outside 
institutions  x       
Flow cytometry  Clinical  * If peripheral blood 
involvement pre -transplant, if 
bone marrow not obtained  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
β-2 microglobulin  Clinical     x  x   
LDH  Clinical    x x x x x x 
Imaging  
 CT chest, abdomen, pelvis  
(neck if indicated)  Clinical  *Day 56 only if abnormal  pre -
transplant   *See 
comment   x x x x x 
GVHD evaluation  Clinical  See text for details    x     
 
 
 
 
 
  
2546.00  - Nonablative  
36 
FHCRC Current Version:  02/06/2018  
 
 Disease  Specimen/ Test/ Imaging  Clinical/ 
Research  Comment  Days  Years  Annual x 
5 years  28 56 84 180 1 1.5 
Mantle Cell 
NHL in 
suspected CR  BM aspirate *in addition to complete NHL restaging  
** If CR documented at one year, and there is recovery of normal blood counts, bone marrow after one year may be obtained based on cli nical judg ment 
 PCR for t(11:14)  Clinical  *If abnormal pre -transplant  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
Peripheral blood  *in addition to complete NHL restaging  
 PCR for t(11:14)  Clinical  *If abnormal pre -transplant, if 
bone marrow not obtained  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
Follicular Cell 
NHL in 
suspected CR  BM aspirate *in addition to complete NHL restaging  
** If CR documented at one year, and there is recovery of normal blood counts, bone marrow after one year may be obtained based on cli nical judg ment 
 PCR for t(14:18)  Clinical  *If abnormal pre -transplant  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
Peripheral blood  *in addition to complete NHL restaging  
 PCR for t(14:18)  Clinical  *If abnormal pre -transplant, if 
bone marrow not obtained  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2546.00  - Nonablative  
37 
FHCRC Current Version:  02/06/2018  
 
 Disease  Specimen/ Test/ Imaging  Clinical/ 
Research  Comment  Days  Years  Annual x 
5 years  28 56 84 180 1 1.5 
MM 
 
 
Omit 
SPEP/IFIX and 
UPEP/IFIX for 
non-secretory 
MM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 BM aspirate *If CR documented at one year, and there is recovery of normal blood counts, bone marrow after one year may be obtained based  on cli nical judg ment 
 Chimerism  Clinical     x  x   
Pathology  Clinical   x x x x x x x 
Flow cytometry  Clinical    x x x x x x x 
Cytogenetics  Clinical  *If abnormal pre -transplant  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
FISH for chrom. 13 (and 
other clonal) abnormalities  Clinical  *If abnormal pre -transplant  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
Peripheral blood  
 Chimerism (CD3+)  Clinical  *Days 56 and 180 only if 
<50% on day 28  x *See 
comment  x *See 
comment  x   
Chimerism (CD33+)  Clinical     x     
Chimerism  (NK CD56+)  Clinical  Optional for outside 
institutions  x       
SPEP and IFIX  Clinical     x x x x x 
Quantitative Ig levels  Clinical  *If abnormal pre -transplant    *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
β-2 microglobulin  Clinical     x x x x x 
Cryoglobulins, C -reactive 
protein, viscosity  Clinical  *If abnormal pre -transplant    *See 
comment  *See 
comment  *See 
comment   *See comment  
Urine  
 Protein/creatinine 
clearance  Clinical     x x x x x 
UPEP and IFIX  Clinical  *If abnormal pre -transplant    *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
Imaging  
 Complete skeletal survey  Clinical       x  x 
Skeletal MRI  Clinical       x  x 
GVHD evaluation  Clinical  See text for details    x     
 
 
 
 
 
2546.00  - Nonablative  
38 
FHCRC Current Version:  02/06/2018  
 
 Disease  Specimen/ Test/ Imaging  Clinical/ 
Research  Comment  Days  Years  Annual x 
5 years  28 56 84 180 1 1.5 
Walden strom’s 
Macro -
globulin emia  
 
Omit 
SPEP/IFIX and 
UPEP/IFIX for 
non-secretory 
Waldenstrom’s 
Macro -
globulinemia  
 BM aspirate * If CR documented at one year, and there is recovery of normal blood counts, bone marrow after one year may be obtained based on cli nical judg ment 
 Chimerism  Clinical     x  x   
Pathology  Clinical   x x x x x x x 
Flow cytometry  Clinical   x x x x x x x 
Cytogenetics  Clinical  *If abnormal pre -transplant  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
FISH for chrom. 13 (and 
other clonal) abnormalities  Clinical  *If abnormal pre -transplant  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
          
Peripheral blood  
 
 Chimerism (CD3+)  Clinical  *Days 56 and 180 only if 
<50% on day 28  x *See 
comment  x *See 
comment  x   
Chimerism (CD33+)  Clinical     x     
Chimerism  (NK CD56+)  Clinical  Optional for outside 
institutions  x       
SPEP and IFIX  Clinical     x x x x x 
Quantitative Ig levels  Clinical  *If abnormal pre -transplant    *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
β-2 microglobulin  Clinical      x x x x 
Cryoglobulins, C -reactive 
protein, viscosity  Clinical  *If abnormal pre -transplant    *See 
comment  *See 
comment  *See 
comment   *See comment  
Urine  
 
 Protein/ creatinine 
clearance  Clinical     x x x x x 
UPEP and IFIX  Clinical  *If abnormal pre -transplant    *See 
comment  *See 
comment  *See 
comment  *See 
comment  *See comment  
Imaging           
 CT chest, abdomen, pelvis  
(neck if indicated)  Clinical  *Day 56 only if abnormal  pre -
transplant   *See 
comment  x x x x x 
GVHD  evaluation  Clinical  See text for details    x     
 
 
2546.00  - Nonablative  
39 
FHCRC Current Version:  02/06/2018  
 
 Table 9: Additional Lab Instructions  (for patients enrolled at FHCRC)  
Note: All bone marrow tests are done on aspirate unless specifically identified as biopsy. All 
instructions apply to both pre - and post -transplant evaluations unless specifically identified 
otherwise.  Volumes represent desired amounts.  
 
Specimen /  
Test Type  Instructions  Lab Name  Contact Information  
Bone marrow  
 Chimerism  Clinical  1-3mL bone marrow in 
green -top tube  Clinical Immunogenetics 
Lab Seattle Cancer Care Alliance  
 (206) 606-7700  
Pathology 
(aspirate ) Clinical  2mL bone marrow in EDTA 
formalin  SCCA Pathology Lab  Seattle Cancer Care Alliance  
(206) 606-1355  
Pathology ( biopsy ) Clinical  1cm bone marrow in 
formalin OR mounted in 
paraffin  SCCA Pathology Lab  Seattle Cancer Care Alliance  
 (206) 606-1355  
Flow Cytometry  Clinical  2mL bone marrow in green -
top tube  UW Hematopathology Lab  Seattle Cancer Care Alliance  
 (206) 606-7060  
Cytogenetics  Clinical  3mL bone marrow in green -
top tube  SCCA Cytogenetics Lab  Seattle Cancer Care Alliance  
 (206) 606-1390  
FISH  Clinical  2mL bone marrow in green -
top tube  SCCA Cytogenetics Lab  Seattle Cancer Care Alliance  
 (206) 606-1390  
PCR  for bcr -abl 
and p190 and/or 
p210  Clinical  3mL bone marrow in 
lavender -top tube  
Label “protocol 2546”  UW Molecular 
Hematopathology Lab  Mailstop G7 -800 825 Eastlake Ave, 
East Seattle, WA 98109  
(206) 606-7060  
PCR t(11:14) or 
t(14:18)  Clinical  2mL bone marrow in 
lavender -top tube  UW Molecular 
Hematopathology Lab  Mailstop G7 -800 825 Eastlake Ave, 
East Seattle, WA 98109  
(206) 606-7060  
Peripheral blood  
 Chimerism  
(CD3+), (CD33+) 
NK(CD56+)  Clinical  10mL blood in green -top 
tube for Flow sorting, then 
to CIL  UW Hematopathology Lab,  
routed to Clinical 
Immunogenetics Lab  Mailstop G7 -800 825 Eastlake Ave, 
East Seattle, WA 98109  
(206) 606-7060  
Flow Cytometry  Clinical  10mL blood in green -top 
tube UW Hematopathology Lab  Seattle Cancer Care Alliance  
 (206) 606-7060  
SPEP/IFIX  Clinical  3mL blood in red -top tube  UW Department of 
Laboratory Medicine  University of Washington  
(800) 713 -5198  
Quantitative Ig 
Levels  Clinical  3mL blood in red -top tube  SCCA Alliance Lab  Seattle Cancer Care Alliance  
(206) 606-2057  
β-2 Microglobulin  Clinical  3mL blood in red -top tube  UW Department of 
Laboratory Medicine  University of Washington  
(800) 713 -5198  
LDH  Clinical  3mL blood in red -top tube  SCCA Alliance Lab  Seattle Cancer Care Alliance  
(206) 606-2057  
PCR for bcr -abl 
and p190 and/or 
p210  Clinical  7mL blood in lavender -top 
tube 
Label “protocol 2546”  UW Molecular 
Hematopathology Lab  Mailstop G7 -800 825 Eastlake Ave, 
East Seattle, WA 98109  
(206) 606-7060  
PCR for t(11:14) or 
t(14:18)  Clinical  5mL blood in lavender -top 
tube UW Molecular 
Hematopathology Lab  Mailstop G7 -800 825 Eastlake Ave, 
East Seattle, WA 98109  
(206) 606-7060  
ZAP – 70 by Flow 
cytometr y 
(pre-transplant 
only) Clinical  5mL blood in green -top 
tube UW Hematopathology Lab  Mailstop G7 -800 825 Eastlake Ave, 
East Seattle, WA 98109  
(206) 606-7060  
 
 
2546.00  - Nonablative  
40 
FHCRC Current Version:  02/06/2018  
 
 EVALUATION OF DONORS  
 
See Standard Practice Manual for standard Evaluation Guidelines  of allogeneic PBSC donors.   
Evaluation of donors at external sites will be per the local standard practice.  
 
11.1 Safety Evaluations  
 
Laboratory parameter  monitoring : Rhabdomyolysis  (defined as a creatine phosphokinase [CPK] 
value > 10fold the upper limit of normal) and hepatocellular injury  are infrequent yet potentially 
serious complications of statin treatment. Therefore, serum levels of CPK and transaminases 
will be assessed befor e initiation of atorvastatin treatment (baseline) and at its completion (first 
day of leukapheresis).  
 
Muscular symptom  monitoring : Because rare cases of rhabdomyolysis have been reported with 
atorvastatin (approximately 1 in 1,000 patients), donors will b e instructed to report any new 
muscle symptoms (i.e. myalgias, tenderness, weakness) while taking atorvastatin. Taking into 
account that G -CSF (Neupogen™) frequently causes musculoskeletal symptoms, any 
symptoms temporally related to atorvastatin treatment  considered significant according to the 
medical team’s assessment will be evaluated at the attending physician’s discretion.  
 
Liver dysfunction  monitoring : Persistent elevations in serum transaminases occurred in 0.7% of 
patients who received atorvastatin  in clinical trials and, in most cases, were not associated with 
clinical symptoms. Transaminase elevations related to atorvastatin treatment are usually 
reversible after discontinuation of the drug and measurements of serum transaminase levels are 
general ly not recommended until completion of 12 weeks of atorvastatin treatment. As outlined 
under ”Laboratory parameter monitoring”, serum levels of transaminases will be assessed 
before initiation of atorvastatin treatment (baseline) and at its completion (fir st day of 
leukapheresis). If clinically indicated, additional measurements of serum transaminase levels 
may be performed at the attending physician’s discretion.  
 
Monitoring for other symptoms : Any new and unexplained significant signs or symptoms 
occurrin g in statin -treated donors should be evaluated according to the judgment of the 
attending physician. Approximately one week after init iation of statin therapy, at the time of 
PBSC collection and one week after donation and discharge from the center, the donor will be 
contacted by study staff (at the local transplant center  or by telephone) to follow up on potential 
adverse effects that ma y require further evaluation. At the same time, the donor will also be 
asked about his/her compliance with the prescribed atorvastatin medication.  
 
If the donor develops clinical signs or symptoms deemed serious and at least possibly related to 
statin trea tment, the attending physician, in consultation with the Principal Investigator, will 
decide whether atorvastatin treatment should be discontinued. In this case, the donor will be 
provided with an appropriate follow -up plan, which will be formulated by the  attending physician 
and the PI.  
 
 
 
11.2 Donor Statin Compliance  
 
Donor compliance with taking atorvastatin will be monitored at the time of each donor contact 
specified above in Section 11.1.  
2546.00  - Nonablative  
41 
FHCRC Current Version:  02/06/2018  
 
  
TOXICITIES AND COMPLICATIONS  
 
For the purposes of this protocol, toxicity will be graded using the modified NCI common toxicity 
scale  version 4.0.  
 
12.1 Atorvastatin  
• Skeletal Muscle  
Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been 
reported with atorvastatin (<1 in 1,000 patients) . A history of renal impairment may be a risk 
factor for the development of rhabdomyolysis. Patients with renal impa irment therefore merit 
closer monitoring for skeletal muscle effects.  Atorvastatin, like other statins, occasionally causes 
myopathy, defined as muscle aches or muscle weakness in conjunction with increases in CPK 
values >10 times ULN. The concomitant use of higher doses of atorvastatin with certain drugs 
such as cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and HIV 
protease inhibitors) increases the risk of myopathy/rhabdomyolysis. Myopathy should be 
considered in any patie nt with diffuse myalgias, muscle tenderness or weakness, and/or marked 
elevation of CPK. Patients should be advised to report promptly unexplained muscle pain, 
tenderness, or weakness, particularly if accompanied by malaise or fever. Atorvastatin therapy 
should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or 
suspected.  
 
Atorvastatin therapy should be temporarily withheld or discontinued in any patient with an acute, 
serious condition suggestive of a myopathy or having a ri sk factor predisposing to the 
development of renal failure secondary to rhabdomyolysis (e.g., severe acute infection, 
hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders, and 
uncontrolled seizures).  
 
• Liver Dysfunction  
Atorvastatin has been associated with biochemical abnormalities of liver function. Persistent 
elevations (>3 times the ULN occurring on 2 or more occasions) in serum transaminases 
occurred in 0.7% of patients who received atorvastatin in clinical trials. The incidence of these 
abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively. One 
patient in clinical trials developed jaundice. Increases in LFTs in other patients were not 
associated with jaundice or oth er clinical signs or symptoms. Upon dose reduction, drug 
interruption, or discontinuation, transaminase levels returned to or near pretreatment levels 
without sequelae. Eighteen of 30 patients with persistent LFT elevations continued treatment 
with a reduc ed dose of atorvastatin.  
 
It is generally recommended that liver function tests be performed prior to and at 12 weeks 
following both the initiation of therapy and any elevation of dose, and periodically (e.g., 
semiannually) thereafter. Liver enzyme changes  generally occur in the first 3 months of 
treatment with atorvastatin. Patients who develop increased transaminase levels should be 
monitored until the abnormalities resolve. Should an increase in ALT or AST of >3 times ULN 
persist, reduction of dose or wi thdrawal of atorvastatin is recommended. Atorvastatin should be 
used with caution in patients who consume substantial quantities of alcohol and/or have a 
history of liver disease. Active liver disease or unexplained persistent transaminase elevations 
are c ontraindications to the use of atorvastatin.  
 
• Endocrine Function  
2546.00  - Nonablative  
42 
FHCRC Current Version:  02/06/2018  
 
 Statins interfere with cholesterol synthesis and theoretically might blunt adrenal and/or gonadal 
steroid production. Clinical studies have shown that atorvastatin  does not reduce basal plasm a 
cortisol concentration or impair adrenal reserve. The effects of statins on male fertility have not 
been studied in adequate numbers of patients. The effects, if any, on the pituitary -gonadal axis 
in premenopausal women are unknown. Caution should be exe rcised if a statin is administered 
concomitantly with drugs that may decrease the levels or activity of endogenous steroid 
hormones, such as ketoconazole, spironolactone, and cimetidine.  
 
• CNS Toxicity  
Brain hemorrhage, optic nerve vacuolation and degeneration, and CNS vascular lesions were 
seen after long -term treatment of normal dogs with atorvastatin or similar drug s in this class at 
doses that produced plasma drug levels 6 -30 times higher than those  attainable  in humans 
taking the highest recommended statin dose.  
 
 
 
• Additional Adverse Reactions  
Clinical Trial Adverse Experiences : In the Lipitor™ -placebo -controlled clinical trial data base of 
16,066 patients (8755 atorvastatin vs. 7311 placebo; age range 10 –93 years, 39% women, 91% 
Caucasians, 3% Blacks, 2% Asians, 4% other) with a median treatment duration of 53 weeks, 
9.7% of patients on atorvastatin and 9.5% of the patients on placeb o discontinued therapy due 
to adverse reactions regardless of causality. The five most common adverse reactions in 
patients treated with atorvastatin that led to treatment discontinuation and occurred at a rate 
greater than placebo were: myalgia (0.7%), di arrhea (0.5%), nausea (0.4%), alanine 
aminotransferase increase (0.4%), and hepatic enzyme increase (0.4%). The most commonly 
reported adverse reactions (incidence ≥ 2% and greater than placebo) regardless of causality, 
in patients treated  with atorvastati n in placebo controlled trials (n=8755) were: nasopharyngitis 
(8.3%), arthralgia (6.9%), diarrhea (6.8%), pain in extremity (6.0%), and urinary tract infection 
(5.7%).  Table 13 summarizes the frequency of clinical adverse reactions  from 17 placebo -
controlled trials, regardless of causality, reported in ≥ 2% and at a rate greater than placebo in 
patients treated with atorvastatin (n=8755).  
2546.00  - Nonablative  
43 
FHCRC Current Version:  02/06/2018  
 
 Table 13. Clinical adverse reactions occurring in > 2% in patients treated with any dose of 
atorvast atin (Lipitor™) and at an incidence greater than placebo regardless of causality (% of 
patients).  
 
 
 
Other adverse reactions reported in placebo -controlled studies include : 
Body as a whole : malaise, pyrexia; Digestive system: abdominal discomfort, flatulence, 
hepatitis, cholestasis;  Musculo -skeletal system : musculoskeletal pain, muscle fatigue, neck 
pain, joint swelling; Metabolic and nutritional system : transaminases increase, LFT abnormal ity, 
blood alkaline phosphatase increa se, serum CPK  increase, hyperglycemia; Nervous system : 
nightmare; Respiratory system: epistaxis; Skin and appendages : urticaria; Special senses : 
vision blurred, tinnitus; Urogenital system: white blood cells urine positive.  
 
12.2 GVHD  
Acute and chronic GVHD are well -recognized complications of allogeneic hematopoietic cell 
transplantation. GVHD will be assessed according to criteria summarized in Appendices B, C 
and D.  Recommended primary systemic treatment for acute GVHD will be cortic osteroids. Other 
systemic immunosuppressive medications may be used at the discret ion of the attending 
physician.  
 
12.3 Total Body Irradiation (TBI)  
TBI will be given in one 200  cGy or up to 400 cGy fraction (per institutional guidelines) from 
linear accelerator at a rate of 6 - 7 cGy/min. Dosimetry calculations are performed by the 
radiation therapist. At the dose  used, side effects are not expected. Nevertheless, there may be 
fever, alopecia, parotitis, diar rhea, reversible skin pigmentation, mucositis and late effects 
including cataract formation, growth retardation, pulmonary damage, carcinogenesis, and 
sterilization.  
 
2546.00  - Nonablative  
44 
FHCRC Current Version:  02/06/2018  
 
 12.4 Cyclosporine (CSP)  
See section 9.2. for information  about administration and dose adjustment . Side effects are 
generally reversible, and may include renal insufficiency, hypomagnesemia, paresthesias, 
tremor, seizures, visual disturbances, paresis, disorientation, depression, confusion, 
somnolence, coma, na usea, hypertension, hemolytic -uremic syndrome, hyperglycemia, 
gynecomastia, and hypertrichosis  
 
12.5 Mycophenolate Mofetil (MMF)  
See section 9.2. for information about administration and dosage adjustments.  
 
Precautions:   MMF has been studied extensively among patients after nonmyeloablative HCT. 
Previous clinical studies in patients after allografting suggest that the principal adverse reactions 
associated with the administration of MMF include nausea, vomiting, neutropenia, diarrhea. In 
the setting of ma rrow transplantation, several etiologic factors may contribute to alterations in 
gastrointestinal and hematologic parameters. MMF has an increased incidence of digestive 
system adverse events, including GI tract ulceration, and hemorrhage (3% of patients r eceiving 
MMF). GI tract perforations have rarely been observed. Most patients in these studies were also 
on other drugs known to be associated with these complications. Up to 2% of patients receiving 
MMF for prevention of rejection developed severe neutrop enia (ANC <500). The development 
of neutropenia may be related to MMF itself, concomitant medications, viral infections or some 
combination of these causes. MMF dose adjustments will be made if clinically indicated if in the 
opinion of the attending physic ian, no other cause is thought to be responsible for the 
abnormality.  These adjustments should be discussed with the principal investigator and 
documented in the medical records and the clinical reporting form (CRF).  
 
12.6 Fludarabine  
The dose of fludarabine used in this protocol is nonmyeloablative, but does  cause significant 
immunosuppression. Fludarabine can lower the white blood cell count, in particular the CD4+ T -
cells. The immunosuppression observed with the use of fludarabine increases the risk of 
infection, which can be life threatening.  
 
12.7 Myelosuppres sion 
Grade IV myelosuppression will be defined as a decrease in ANC to <500/µL and/or platelet 
count to  20,000/µL. If myelosuppression occurs, a bone marrow aspirate and biopsy should 
be considered to exclude disease progression. Samples should be sent f or chimerism analysis. 
Myelosuppression may occur in this patient population for a number of reasons such as direct 
toxic effect of drugs (MMF, ganc iclovir etc.), rejection, relapse or after DLI.  
 
 
 
ADVERSE EVENT MONITORING  
 
13.1 Institutional Policy and Definitions  
 
• Policy  
2546.00  - Nonablative  
45 
FHCRC Current Version:  02/06/2018  
 
 The following guidelines are the minimum Cancer Consortium IRB adverse e vent (AE) reporting 
guidelines.  
In accordance with institutional policy, all serious adverse events (SAEs) which in the opinion of 
the principal investigator are unexpected and related or possibly related to the research and 
serious or suggest that the research places research participants or others at greater risk of 
physical or psychological harm than was pre viously known or recognized must be reported to 
the IRB within 10 calendar days of learning of the problem. Since only stem cell donors and 
not recipients will be treated with atorvastat in according to this study, monitoring of  non-
serious  AEs will focus o n the  donors . Non-serious AEs occurring in the patient will not 
be collected.  The Cancer Consortium Expedited Reporting Form for Unanticipated Problems or 
Noncompliance should be completed for all adverse events that meet the expedited reporting 
requiremen ts. The form should be sent to the Institutional Review Office (IRO) within 10 
calendar days of learning of the problem . 
SAE Policy and Reporting at External Sites :  For SAEs that occur in patients enrolled at 
external sites, reporting to the local IRB will be per the local institutional policy.  This will apply to 
expedited and annual reporting.  It will be the responsibility of the external site to submit to 
FHCRC an SAE report for all SAEs that occur in patients and donors.  These report s must be 
sent to FHCRC within 10  days of learning of the event.    
Please see Appendix F for definitions of adverse events, serious adverse events (SAE) and 
serious and unexpected eve nts as well as mechanisms for reporting these events  
 
13.2 Adverse Events to be Monitored in This Study  
 
• Serious Adverse Events   
- SAEs:  All events occurring in donors and recipients that meet the definition of an SAE will be 
recorded  and reported to the IRB , regardless of whether they are related or unrelated to the 
protocol intervention or are expected or unexpected.  SAEs observed in donors or recipients that 
are deemed related or possibly related and unexpected to the research will be reported to th e 
IRB in an expedited fashion (within 10 calendar days of learning of the problem). All other SAEs 
will be reported to the IRB at the time of annual protocol renewal.  
 
• Adverse Events Related to Administration of Atorvastatin  
o Select t oxicities will be collected using the  National Cancer Institute (NCI) Common 
Toxicity Criteria for Adverse Events (CTCAE), version 4.0  (Appendix I) 
o Since the primary research intervention in this study is the administration of atorvastatin 
to PBSC donors before stem cell collection  (for prevention of severe acute GVHD  in 
recipients) , reporting of AE s that are not serious  will focus on atorvastatin -related events  
in donors . Although highly unlikely, the potential negative impact of donor statin 
treatment on recipient outcomes will be captured through no -harm endpoints that trigger 
mandatory DSMB review  as further outlined in 17.3.  
o Donors  will be assess ed for the following events:  
▪ Musculoskeletal and connective tissue disorders : grade 2 -5 
▪ Hepatobiliary disorders : grade 2 -5 
▪ Other  unexpected events thought related to the use of atorvastatin; grade 2 -5 
In cases where the NCI criteria do not apply, intensity will be defined as:  
2546.00  - Nonablative  
46 
FHCRC Current Version:  02/06/2018  
 
 ▪ Mild: awareness of symptom or sign, but easily tolerated  
▪ Moderate: discomfort is enough to cause interferen ce with normal activities  
▪ Severe: inability to perform normal daily activities  
▪ Life threatening: immediate risk of death from the reaction as it occurred  
 
 
 
  
2546.00  - Nonablative  
47 
FHCRC Current Version:  02/06/2018  
 
   
 
 
 
 
 
 
 
                                                                           
 
 
 
 
 
 
 
 
 
                                                                      
 
 
 
 
 
 
 
 
                                                                              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13.3  Duration of Adverse Event and Unanticipated Problem Monitoring and 
Recording  
Donor : SAEs  and select AEs (see section 13.2 ) will be monitored and recorded from the time 
the donor starts atorvastatin therapy through 7 days after the discontinuation of the medication . 
 Figure 3 : SAE reporting  for patients on Protocol 2546 as an independent 
primary treatment  Protocol or as an adjunct:  
 
 
Protocol 2546 serves 
as adjunct protocol  
 Protocol 2546 
serves as an 
independent primary 
treatment protocol  
 
Utilize adapted CTC 
version of primary 
protocol for toxicities  
 Utilize adapted CTC 
v.4.0 (Appendix J) 
 
SAEs and AEs are 
reported to the IRB 
on the primary 
protocol AND on 
Protocol 2546  
 SAEs and AEs are 
reported to the IRB 
as Protocol 2546 
events  
 
Donor events are 
ONLY reported on 
Protocol 2546  
2546.00  - Nonablative  
48 
FHCRC Current Version:  02/06/2018  
 
 Recipient : SAEs (life -threatening or fatal)  
• For 2546 as an adjunct to treatment plan or primary protocol , SAEs will be 
monitored and recorded from the time the recipient starts conditioning therapy through 
day 100 or discharge from the center, whichever occurs earlier.  
 
• For 2546 as an adjunct to a nonmyeloblative investigational protocol , follow 
reporting guidelines of nonmyeloblative investigational protocol.  
 
 
OUTCOMES TO BE ASSESSED  
 
14.1 Proportion of Donors who Discontinue Atorvastatin Bec ause of Toxicity  
During treatment with atorvastatin, donors will be evaluated for adverse effects that would 
mandate discontinuation of the drug. Data pertaining to atorvastatin toxicity including those 
mandating  discontinuation of the drug will be collect ed per Section 13 . 
 
14.2 Acute GVHD  
All patients will be evaluated for GVHD. It is strongly recommended, when possible, that 
biopsies be taken for histological confirmation of GVHD. The final peak grade of GVHD will be 
determined retrospectively by Dr. Paul Martin. Data pertaining to the diagnosis and treatment of 
acute GVHD will be collected though day +100 post -transplant.   
 
14.3 Chronic GVHD  
Patients will be evaluated for chronic GVHD as described in the NIH consensus project 
guidelines.  Graft failure, recurrent malignancy and death without GVHD are considered to be 
competing risks for GVHD.   
 
14.4 Recurrent Malignancy  
Recurrent malignancy wil l be defined by hematologic criteria. Recurrent malignancy will also be 
defined as any unplanned medical intervention designed to prevent progression of malignant 
disease in patients who have molecular, cytogenetic or flow -cytometric evidence of malignant 
cells after transplantation.  
 
14.5 Non-relapse Mortality (NRM)   
NRM is defined as death in the absence of recurrent or progressive malignancy after HCT.  
 
14.6 Overall Survival (OS)  
Survival without death (OS) will be determined and presented as Kaplan -Meier estimates at 1 
year post -transplant.   
 
2546.00  - Nonablative  
49 
FHCRC Current Version:  02/06/2018  
 
 14.7 Proportion of Patients Requiring Secondary Systemic  Immunosuppressive  
Treatment   
The need for additional systemic immunosuppressive treatment with agents other than those 
used for prophylaxis  and initial therapy , the reason for their administration (acute GVHD, chronic 
GVHD, or other reasons) will be determined.  
 
DATA AND SAFETY MONITORING PLAN  
 
15.1 Principal Investigator  
  
• Responsibilities  
o Coordinating development of the protocol as well as its subsequent 
amendments.  
o Securing initial IRB and NHLBI approval of the protocol  
o Securing IRB approval of protocol amendments.  
o Reviewing and adjudicating whether SAEs are unexpected and related to 
administration of atorvastatin to donors before stem c ell collection.   
o Securing renewal of IRB approval at annual intervals.  
 
• Oversight Mechanisms  
To identify trends pertinent to patient or donor safety, t he Principal Investigator will meet with 
the research nurse and other key investigators to review enrollment, SAEs  and AEs in the 
donors that might be related to administration of atorvastatin . Patient data (day 100 NRM and 
recurrent malignancy) will  also be reviewed .   
 
15.2 Data Safety Monitoring Board (DSMB)  
 
• Role of the DSMB  
This stud y will be monitored by a DSMB. The primary role of the DSMB will be to monitor 
proto col specific AEs and SAEs  in the donors , even though occurrence of SAEs in donors 
probably or likely related to short -term atorvastatin treatment is considered highly unli kely.  The 
DSMB will monitor acute GVHD, relapse, non -relapse mortality and overall survival in the 
patients.    
 
• DSMB Membership  
Membership will consist of one statistician and two senior physicians who are familiar with HCT.  
To avoid any conflict of inter est, DSMB members are required to have no study involvement. 
Potential conflicts of interest will be reviewed by the IRB at the time of initial DSMB 
appointment.  
 
• Operations and Responsibilities of the DSMB  
The DSMB will meet after the first cohort of 13 donors  have  completed the stem cell donation 
process. Subsequent meetings will be held at 12-month intervals.  At each meeting the DSMB 
will review data related to donor  and patient safety. It is anticipated that the donor safety 
monitoring will include a review of all protocol -specific adverse events an d AEs  and SAEs. Even 
though there has been no indication based on large retrospective analyses that donor statin 
2546.00  - Nonablative  
50 
FHCRC Current Version:  02/06/2018  
 
 treatment may negatively affect recipients’ outcomes [2], rates of recurrent malignancy and day -
100 mortality in recipients will be carefully monitored and considered during DSMB review.  
Based on the information available at each of these meetings, the DSMB is charged with 
deciding whether a) no action is required, b) the protocol should be modified, c) further 
enrollment should be suspended pending additional review, or d) the protocol s hould be closed.   
The DSMB will keep minutes of its meetings and provide its findings to the Principal Inves tigator 
within 10 working days.  An exception to this time requirement will occur if the DSMB 
recommends study termination, suspension of enrollment  or a protocol modification that 
significantly affects donor or patient safety. In these cases, the DSMB will be expected to 
provide their recommendations to the Principal Investigator within 24 hours. Ad hoc meeting or 
discussion with the DSMB will be arr anged as deemed necessary by the protocol PI.   
 
• Reporting Data to the DSMB  
The Principal Investigator will be responsible for providing the DSMB with summary data 
sufficient to meet its responsibilities.   
 
15.3  Trial Monitoring  
Trial monitoring is provi ded in accordance with the FHCRC/University of Washington (UW) 
Cancer Consortium Data and Safety Monitoring Plan (DSMP). Under the provisions of the 
DSMP, the Cancer Consortium Clinical Trial Support Office provides monitoring for quality 
process and compl iance by qualified monitors unaffiliated with the conduct of the study. 
Monitoring visits occur at specified intervals determined by the assessed risk level of the study 
and the findings of the previous visit. The scope of monitoring is specified in the DS MP 
http://www.cancerconsortium.org/rto/prr/   
Per FHCRC IRB Policy 1.9, all confirmed serious or continuing noncompliance with federal laws 
relating to research involving human subjects, the FHCRC hum an subject protection program 
(HRPP) or the requirements of the IRB will be reported promptly to either the IRO Director or 
other entities cited in the policy.  
 
 
DATA MANAGEMENT AND PROTECTION OF CONFIDENTIALITY  
Clinical Statistics maintains a subject database at FHCRC to allow storage and retrieval of  local 
subject data collected from a wide variety of sources. The investigator will ensure that data 
collected conform to all established guidelines for coding, collection, key entry and verificati on. 
Each subject is assigned a unique patient number to assure subject confidentiality. Subjects will 
not be referred to by this number, by name, or by any other individual identifier in any 
publication or external presentation. The licensed medical record s department, affiliated with the 
Consortium  institution where the subject receives medical care, maintains all original inpatient 
and outpatient chart documents. Subject research files are scanned and stored securely in an 
optical web library (OWL). OWL r ecords are maintained by the FHCRC data abstraction staff. 
Access is restricted to personnel authorized by the Division of Clinical Research.  
 
  
2546.00  - Nonablative  
51 
FHCRC Current Version:  02/06/2018  
 
 Table  14. Confidence  of that a true rat e of grade 3 -4 acute 
GVHD of <9 % exists as a function of  increasing numbers of 
patients in whom grade 3 -4 acute GVHD is observed.  
N cases 
GVHD  Confidence  
< 9% Power1 if 
True =  4% Power1 if 
True =  2% 
0 >99 2 13 
1 >99 9 40 
2 >99 23 68 
3 98  43 86 
4  95   63 95 
5  90  79 98 
6 81  89 >99 
1Probability of observing indicated number of cases or fewer 
among a total number of 100 patients  STATISTICAL CONSIDERATIONS  
 
17.1  Primary Endpoint and Sample Size  
The primary endpoint of this study is the proportion of patients who develop grade 3 -4 acute 
GVHD  after transplantation. The cumulative incidence of this endpoint in patients prepared with 
nonmyeloablative conditioning regimens after HCT from HLA -matched related donors, and with 
CSP-based immunosuppression is approximately 9 %. A reduction in the cumul ative incidence 
of acute GVHD from 9% to <2 % would represent a reasonable goal after nonmyeloablative HCT 
and constitute study success . Patients with GVHD symptoms that are equivocal with respect to 
assigning severity and grade will be reviewed by at least  two GVHD attendings to arrive at 
consensus grading. Based on a hypothetical total of 100 patients evaluated, Table 14 illustrates 
the decreasing confidence that a true rate of grade 3 -4 acute GVHD of <9% exists 
corresponding to increasing numbers of patie nts in whom grade 3 -4 acute GVHD is observed. 
Having 90% confidence that a true grade 3 -4 GVHD rate of <9% exists appears sufficient to 
define success of this study; therefore, donor/patient pairs would be enrolled until the 6th patient 
develops grade 3 -4 acute GVHD. If a 6th patient develops grade 3 -4 acute GVHD, the study 
would be closed for lack of demonstrable efficacy. Patients with GVHD symptoms that are 
equivocal with respect to assigning severity and grade will be reviewe d by at least two GVHD 
attendings to arrive at consensus grading.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stopping rules  will be imposed for:  
 
• Grade 3 -4 acute GVHD in 6/100 patients  
 
Patients who have to discontinue CSP because of toxicity before onset of GVHD and who 
subsequently develop grade 3 -4 acute GVHD will not be considered for assessment of efficacy. 
As long as <6 patients have developed grade 3 -4 acute GVHD, the study would c ontinue to 
enroll up to a maximum of 100 donor/recipi ent pairs.  
 
2546.00  - Nonablative  
52 
FHCRC Current Version:  02/06/2018  
 
 17.2 Secondary Endpoints  
 
• Acute and chronic GVHD  
Grades II -IV and II -IV acute GVHD and chronic GVHD will be assessed with the use of 
cumulative incidence plots.  
 
• Non-relapse Mortality  
Non-relapse mortality will be assessed with the use of cumulative incidence plots. This 
secondary endpoint will be characterized and presented as a cumulative incidence a t day 100 
and at 1 year after HC T. 
 
• Recurrent or p rogressive Malignancy  
Recu rrent or progressive malignancy will be assessed with the use of cumulative incidence 
plots.  
  
• Overall survival  
Disease -free survival and overall survival will be evaluated as Kaplan -Meier estimates at 1 year 
after HCT.  
  
• Duration of Systemic Immunosuppres sive Treatment  
Primary and secondary treatment of acute GVHD and withdrawal of systemic 
immunosuppressive treatment will be assessed with the use of cumulative incidence plots.  
 
•  Discontinuation of Atorvastatin Therapy  
The number of donors who prematurely discontinue atorvastatin therapy and the reasons for 
discontinuation will be described.   
 
 
17.3 Mandatory Ad Hoc  DSMB Review   
 
This protocol  is designed to  evaluate GVHD -protective effects associated with donor statin 
treatment as a novel approach to immunosuppression after nonmyeloablative HCT  from HLA-
matched  related donors. Although deemed extremely unlikely, a n ad hoc  DSMB review will 
be convened  if interim result s raise  concerns  about donor  safety, particularly w ith respect to 
muscle and hepatic toxicity. In large studies using atorvastatin for long-term treatment of 
patients with hyperlipidemia, SAEs were rare (<1%), did not increase across the 10 mg/day to 
80 mg /day dose -range and seldom led to study withdrawal. Based on this review, the DSMB will 
make a determination as to whether the protoco l should  be closed to accrual.   
Even though there has been no indication based on large retrospective analyses that donor 
statin treatment may negatively affect recipients’ outcomes [2], rates of recurrent malignancy 
and day -100 mortality in recipients will be carefully monitored and considered during DSMB 
review. In the unlikely event that there was evidence suggesting donor  statin treatment causes 
harm in recipients, the DSMB may recommend modification or closure of the study.  
 
2546.00  - Nonablative  
53 
FHCRC Current Version:  02/06/2018  
 
 17.4 Projected Ethnic and Gender Distribution  
 
Table 15: ETHN IC AND GENDER DISTRIBUTION CHART  
 
TARGETED / PLANNED ENROLLMENT:  Number of Subjects  
 
Ethnic Category   
Sex / Gender  
 
Females  Males  Total  
Hispanic or Latino  1 2 3 
Not Hispanic or Latino  41 56 97 
Ethnic Category Total of All Subjects*  42 58 100 
Racial Categories  
 
American Indian / Alaska Native  1 1 2 
Asian  1 1 2 
Native Hawaiian or Other Pacific Islander  0 0 0 
Black or African American  1 2 3 
White  39 54 93 
Racial Categories:  Total of All Subjects*  42 58 100 
 
 
 
 
 
TERMINATION OF STUDY  
Participants may withdraw from this study at any time at their discretion. Participants may also 
be removed from this protocol if they develop any untoward side effects from the study 
medications. In addition, stopping rules are in place for lack of effica cy and a DSMB will 
evaluate issues related to excessive toxicity  observed in patients or donors thought to be related 
to atorvastatin.  
 
The PI may terminate the study at any time. The IRB and the United States Food and Drug 
Administration also have the aut hority to terminate the study should it be deemed necessary.  
  
2546.00  - Nonablative  
54 
FHCRC Current Version:  02/06/2018  
 
 REFERENCES  
 
 1.   Rotta M, Storer BE, Storb RF, Martin PJ, Heimfeld S, Peffer A, Maloney DG, Deeg HJ, Sandmaier 
BM, Appelbaum FR, Mielcarek M. Donor statin treatment protects against severe acute graft -
versus -host disease after related allogeneic hematopoietic cell transplantation. Blood. 
2010;115:1288 -1295.  
2.  Rotta M, Storer BE, Storb R, Martin PJ, Flowers MED, Vernon MS, Peffer A, Maloney DG, Deeg 
HJ, Sandmaier BM, Appelbaum FR, Mi elcarek M. Impact of recipient statin treatment on graft -
versus -host disease after allogeneic hematopoietic cell transplantation. Biol of Blood Marrow 
Transplant  16:1463 -1466 (2010)  
3.  Zeiser R, Youssef S, Baker J, Kambham N, Steinman L, Negrin RS. Preemptive HMG -CoA 
reductase inhibition provides graft -versus -host disease protection by Th -2 polarization while sparing 
graft-versus -leukemia activity. Blood. 2007;110:4588 -4598.  
 4.  Liao JK , Laufs U. Pleiotropic effects of statins (Review). Annual Review of Pharmacology and 
Toxicology. 2005;45:89 -118. 
 5.  Zeiser R, Maas K, Youssef S, Durr C, Steinman L, Negrin RS. Regulation of different inflammatory 
diseases by impacting the mevalonate pat hway (Review). Immunology. 2009;127:18 -25. 
 6.  Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein 
prenylation to immunomodulation (Review). Nat Rev Immunol. 2006;6:358 -370. 
 7.  Blank N, Schiller M, Krienke S, Busse F,  Schatz B, Ho AD, Kalden JR, Lorenz HM. Atorvastatin 
inhibits T cell activation through 3 -hydroxy -3-methylglutaryl coenzyme A reductase without 
decreasing cholesterol synthesis. J Immunol. 2007;179:3613 -3621 .  
 8.  Hillyard DZ, Cameron AJ, McDonald KJ, Tho mson J, MacIntyre A, Shiels PG, Panarelli M, Jardine 
AG. Simvastatin inhibits lymphocyte function in normal subjects and patients with cardiovascular 
disease. Atherosclerosis. 2004;175:305 -313. 
 9.  Brinkkoetter PT, Gottmann U, Schulte J, van der Woude FJ,  Braun C, Yard BA. Atorvastatin 
interferes with activation of human CD4(+) T cells via inhibition of small guanosine triphosphatase 
(GTPase) activity and caspase -independent apoptosis. Clin Exp Immunol. 2006;146:524 -532. 
 10.  Mausner -Fainberg K, Luboshits  G, Mor A, Maysel -Auslender S, Rubinstein A, Keren G, George J. 
The effect of HMG -CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. 
Atherosclerosis. 2008;197:829 -839. 
 11.  Mira E, Leon B, Barber DF, Jimenez -Baranda S, Goya I, Almonacid L,  Marquez G, Zaballos A, 
Martinez A, Stein JV, Ardavin C, Manes S. Statins induce regulatory T cell recruitment via a CCL1 
dependent pathway. J Immunol. 2008;181:3524 -3534.  
 12.  Schramm R, Menger MD, Harder Y, Schmits R, Adam O, Weitz -Schmidt G, Schafers H J. Statins 
inhibit lymphocyte homing to peripheral lymph nodes. Immunology. 2007;120:315 -324. 
 13.  Weitz -Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, 
Hommel U. Statins selectively inhibit leukocyte function antig en-1 by binding to a novel regulatory 
integrin site. Nat Med. 2001;7:687 -692. 
 14.  Shimabukuro -Vornhagen A, Liebig T, Bergwelt -Baildon M. Statins inhibit human APC function: 
implications for the treatment of GVHD. Blood. 2008;112:1544 -1545.  
 15.  Fehr T, Kahlert C, Fierz W, Joller -Jemelka HI, Riesen WF, Rickli H, Wuthrich RP, Ammann P. 
Statin -induced immunomodulatory effects on human T cells in vivo. Atherosclerosis. 2004;175:83 -
90. 
 16.  Zhang X, Jin J, Peng X, Ramgolam VS, Markovic -Plese S. Simvastatin i nhibits IL -17 secretion by 
targeting multiple IL -17-regulatory cytokines and by inhibiting the expression of IL -17 transcription 
factor RORC in CD4+ lymphocytes. J Immunol. 2008;180:6988 -6996.  
 17.  Hamadani M, Awan FT, Devine SM. The impact of HMG -CoA red uctase inhibition on the incidence 
and severity of graft -versus -host disease in patients with acute leukemia undergoing allogeneic 
transplantation. Blood. 2008;111:3901 -3902.  
  
2546.00  - Nonablative  
55 
FHCRC Current Version:  02/06/2018  
 
  
 
TABLE OF APPENDICES  
 
 Appendix A:  Lipitor (atorvastatin) Product label  
Appendix B: Chronic Graft -Versus -Host Disease Grading  
 Appendix C: Acute GVHD Assessment (by Organ System)  
 Appendix D:  GVHD Assessment Form  
Appendix E: Evaluation of Disease Response  
 Appendix F: The Study Coordinator’s Manual  
 Appendix G: Serious Adverse  Event Report Form  
 Appendix H: Notice of Death Form  
 Appendix I: Coordinating Center Functions  
 Appendix J: Adapted Common Toxicity Criteria, version 4.0  
 Appendix K: Patient Demographics and Registration Form  
 Appendix L: Case Report Form  
 Appendix M:  Donor Safety and Compliance Evaluation  
 Appendix N: The Hematopoietic Cell Transplant -Comorbidity Index (HCT -CI) 
 
2546.00  - Nonablative  
56 
FHCRC Current Version:  02/06/2018  
 
 Appendix A:  Lipitor (atorvastatin) Product labe l 
 
 
 
 
 
 
http://labeling.pfizer.com/ShowLabeling.aspx?id=587  
 
 
2546.00  - Nonablative  
57 
FHCRC Current Version:  02/06/2018  
 
 APPENDIX B : 
 
CHRONIC GRAFT -VERSUS -HOST DISEASE (GVHD)  
 
Chronic GVHD in allogeneic transplant recipients resembles autoimmune disorders such as  
scleroderma, Sjogren syndrome, primary biliary cirrhosis, lichen planus, wasting syndrome,  
bronchiolitis obliterans among others manif estations (see below). Approximately 50% of  
patients will develop this complication within 6 months after the transplant despite continued  
treatment with immunosuppressive medications. Close monitoring is recommended during  
the first 2 years after allogene ic stem cell transplantation so that appropriate treatment can be  
instituted promptly in patients who develop chronic GVHD. Debilitation, joint contractures  
and profound immunosuppression resulting in recurrent bacterial infections are prominent  
characteristics of untreated chronic GVHD.  
 
A. Classification of Chronic GVHD  
The purpose of this classification is to identify patients with cGVHD who need long -term 
systemic immunosuppression according to clinical and laboratory findings and risk factors at  
the time of initial diagnosis.  
 
1.  Chronic GVHD not requiring systemic treatment: mild abnormalities involving a  
single site, with platelet count >100,000 and no steroid treatment at the onset of  
chronic GVHD  
a)  Oral abnormalities consistent with cGVHD, a positive skin or lip biopsy, and no other  
manifestations of cGVHD  
b)  Mild liver test abnormalities (alkaline phosphatase ≤2 x upper limit of normal, AST or  ALT 
≤3 x upper limit of normal and total bilirubin ≤1.6) with positive skin or lip bi opsy,  and no 
other manifestations of cGVHD  
c)  Less than 6 papulosquamous plaques, macular -papular or lichenoid rash involving <20% 
of body surface area (BSA), dyspigmentation involving <20% BSA, or erythema  involving 
<50% BSA, positive skin biopsy, and no  other manifestations of cGVHD  
d)  Ocular sicca (Schirmer’s test ≤5mm with no more than minimal ocular symptoms),  
positive skin or lip biopsy, and no other manifestations of cGVHD  
e)  Vaginal or vulvar abnormalities with positive biopsy, and no other manif estations of  
cGVHD  
 
2.   Chronic GVHD requiring systemic treatment: more severe abnormalities or  
involvement of multiple sites, or platelet count <100,000, or steroid treatment  
at the onset of chronic GVHD  
a)  Involvement of two or more organs with symptoms or signs of cGVHD, with biopsy  
documentation of cGVHD in any organ  
b)  ≥15% base line body weight loss not d ue to other causes, with biopsy documentation of  
cGVHD in any organ  
c)  Skin involvement more extensive than defined for cl inical limited c GVHD, confirmed by 
biopsy  
d)  Scleroderma or morphea  
e)  Onycholysis or onychodystrophy thought to represent cGVHD, with documentation of  
cGVHD in any organ  
f)  Decreased range of motion in wrist or ankle extension due to fasciitis caused by cGVHD  
g)  Cont ractures thought to represent cGVHD  
h) Oral involvement with functional impairment, refractory to topical treatment  
i)  Vaginal involvement with functional impairment, refractory to topical treatment  
j)  Bronchiolitis obliterans not due to other causes  
k)  Positive liver biopsy; or abnormal liver function tests not due to other causes with  
alkaline phosphatase >2 x upper limit of normal, AST or ALT >3 x upper limit of  
normal, or total bilirubin >1.6, and documentation of cGVHD in any organ  
l)  Positive u pper or lower GI biopsy  
2546.00  - Nonablative  
58 
FHCRC Current Version:  02/06/2018  
 
 m)  Fasciitis or serositis thought to represent cGVHD and not due to other causes  
 
B. Physical manifestations of Chronic GVHD  
Manifestations that are distinctive for chronic GVHD can begin before day 100 after the  
transplant, and ma nifestations that are typical of acute GVHD can persist long after day 100.  
For this reason, the differential diagnosis between acute and chronic GVHD cannot be made  
solely according to the time interval from transplant. The diagnosis of chronic GVHD  
requi res at least one manifestation that is distinctive for chronic GVHD ( identified by italic  
print below ) as opposed to acute GVHD. In all cases, infection and others causes must be  
ruled out in the differential diagnosis of chronic GVHD.  
 
Karnofsky or Lansky  Clinical Performance scores <60%, ≥15% weight loss, and recurrent  
infections are usually signs of clinical extensive chronic GVHD. Abnormalities that could  
indicate chronic GVHD are categorized by organ system are listed below ( italic print  
identifies man ifestation more distinct of chronic GVHD):  
 
Skin Erythema, dryness, pruritis, macular -papular or urticarial rash, pigmentary changes (i.e., hyperpigmentation, 
vitiligo), mottling, papulosquamous or lichenoid plaques, hyperkeratosis, exfoliation (icht hyosis), nodules, 
scleroderma, morphea (one or several circumscribed, indurated and shiny lesions) . The extent of skin 
involvement  and the s kin thickness score  for patients with scleroderma needs to be recorded at the time of 
diagnosis, when changes in treatment are made and when assessing treatment response. Medical photos 
are also useful for assessing the extent of skin involvement and response to treatment.  
Nails  B.     Ridging, onychodystrophy, onycholysis  
Hair Premature graying (scalp hair, eyelashes, eyebrows), thinning scalp hair, alopecia, decreased body hair  
Mouth  Dryness, burning, gingivitis, mucositis, striae, dryness, atrophy, erythema, lichenoid changes, ulcers, labial 
atrophy or pigmentary changes, tightness around the mouth, sensitivity to acidic, strong flavors, heat or cold, 
tooth decay  
Eyes  Dryness, burnin g, blurring, gritty eyes, photophobia, pain  
Vagina/vul
va Dryness, dyspareunia, stricture or stenosis, erythema, atrophy or lichenoid changes not induced by ovarian 
failure or other causes  
Liver Jaundice and elevated liver function tests not due to other causes (see laboratory tests)  
Lung  Bronchiolitis obliterans (see diagnostic indicators), cough, wheezing, dyspnea on exertion, history of 
recurrent bronchitis or sinusitis  
GI Anorexia, nausea, vomiting, diarrhea, malabsorption, dysphagia, odynophag ia 
Myofascial  Stiffness and tightness with restriction of movement, occasionally with swelling, pain, cramping, erythema 
and induration, most commonly affecting the forearms, wrists and hands, ankles, legs and feet, inability to 
extend the wrists without flexing the fingers or the elbows, contractures  
Muscle  Proximal muscle weakness, cramping  
Skeletal  Arthralgia of large proximal girdle joints and sometimes smaller joints  
Serosal  
 
 Unexplained effusions involving the pleural, pericardial, or peritoneal cavities not due to venocclusive disease 
of the liver, cardiac insufficiency, malignancy, infection, GM -CSF toxicity or other causes  
 
 
 
 
 
 
 
 
 
 
 
 
 
2546.00  - Nonablative  
59 
FHCRC Current Version:  02/06/2018  
 
 C. Laboratory Testing and Diagnostic Indicators of Chronic GVHD  
 
 
 
D. Guidelines for Treatment of Chronic GVHD after allogeneic HCT  
 
We strongly recommend that you consult the LTFU office before beginning treatment for chronic GVHD 
and before making changes in immunosuppressive treatment. Clinical trials should always be considered 
because current standard therapies are associated with high morbidity and decreased survival for 
patients with high risk chronic GVHD.  
 
Standard treatment of chronic GVHD usually begins with administration of glucocorticoids (1mg/kg/day) 
followed by taper to eventually reach an alternate -day regimen, with or w ithout daily cyclosporine or 
tacrolimus (FK506). Other medications used for treatment of corticosteroid -resistant chronic GVHD are 
summarized on the next page. Telephone consultation with the LTFU medical team is available to you, 
seven days a week, to dis cuss appropriate treatment and provide other follow up recommendations. In 
addition to immunosuppressive treatment, antibiotic prophylaxis for encapsulated bacterial infections and 
PCP must be given to all patients being treated for chronic GVHD  
 
The durat ion of systemic immunosuppressive treatment of chronic GVHD varies but requires at least one 
year of therapy. Approximately 80% of patients require systemic immunosuppressive for 2 years and 40% 
of them requires therapy for at least 4 years.  
 
 
Adapted From : Long -Term Followup After Hematopoietic Stem Cell Transplant General Guidelines For 
Referring Physicians, Fred Hutchinson Cancer Research Center Standard Practice Manual, Section X, 
Chronic Graft Versus Host Disease (GVHD), Nov/2003 Version  
 
  Eye Schirmer’s test with a mean value ≤ 5 mm at 5 minutes, or values of 6 -10 mm in patients who have sicca 
symptoms, or keratitis detected by slit lamp examination  
Liver  Elevated liver function tests not due to other causes (alkaline phosphatase ≥2 x upper li mit, of normal, AST 
or ALT >3 x upper limit of normal or total serum bilirubin ≥1.6)  
Lung  New obstructive lung defect defined as an FEV1 <80% of predicted with either an FEF 25 -75 <65% of 
predicted or RV >120% of predicted, or a decrease of FEV1/FVC by >1 2% within a period of less than 1 
year, thought not to be caused by an infectious process, asthma or recurrent aspiration from the sinuses or 
from gastroesophageal reflux. In the absence of GVHD in any other organ, the diagnosis of bronchiolitis 
obliterans  requires negative microbiological tests from bronchoalveolar lavage, evidence of air trapping by 
high resolution end -expiratory and end -inspiratory CAT scan of the lungs, or confirmation by thoracoscopic 
biopsy.  
Esophagus  Esophageal web formation, stricture or dysmotility demonstrated by barium swallow, endoscopy or 
manometry  
Intestine  Endoscopic findings of mucosal edema and erythema or focal erosions with histological changes of apoptotic 
epithelial cells and crypt cell drop out. Patie nts with unresolved acute GVHD may have more severe 
intestinal mucosal lesions including ulcers and mucosal sloughing.  
Muscle  Elevated CPK or aldolase, EMG findings consistent with myositis with biopsy revealing no other etiological 
process  
Blood  Thrombocytopenia (usually 20,000 -100,000/
 l), eosinophilia (> 0.4 x 103/uL), hypogammaglobulinemia. 
Hypergammaglobulinemia and autoantibodies occur in some cases.  
2546.00  - Nonablative  
60 
FHCRC Current Version:  02/06/2018  
 
   
APPENDIX C 
 
ACUTE GVHD ASSESSMENT  
 
Staging by Individual Organ Involvement  
 
SKIN:  measured by rash first appearing generally between 10 and 70 days after transplant. 
(excludes rashes of known viral or other origin)  
 
Stage  Description  
1 Maculopapular rash <25% BSA  
2 Maculopapular rash 25 – 50% BSA  
3 Generalized erythroderma  
4 Generalized erythroderma with  
bullous formation and desquamation  
 
LIVER*:  measured by total serum bilirubin  
 
Stage  Description  
1 2.0 – 2.9 mg/dL  
2 3.0 – 5.9 mg/dL  
3 6.0 – 14.9 mg/dL  
4 > 15.0 mg/dL  
 
GUT**:  includes only diarrhea occurring after Day +21  
 
Score  Adult  Pediatric***  
1 upper GI (anorexia, nausea, vomiting) 
with diarrhea of <1000 mL/day  upper GI (anorexia, nausea, vomiting) 
with diarrhea of <555 mL/m2/day 
2 1000 – 1499 mL/day diarrhea  556-833 mL/m2/day diarrhea  
3 > 1500 mL/day diarrhea  >833 mL/m2/day diarrhea  
4 severe abdominal cramping, bleeding or ileus caused by GVHD  
 
* In cases where another cause of hyperbilirubinemia antedated the onset of rash, the liver score 
should be decreased by one stage.  
** In cases where peak GI symptoms are exacerbated by a cause other than GVHD, the gut score 
should be decreased by one stage.  
*** Pediatric patients <17 year s of age  
2546.00  - Nonablative  
61 
FHCRC Current Version:  02/06/2018  
 
 APPENDIX C continued  
 
ACUTE GVHD ASSESSMENT  
 
Overall Grade  
 
The determination of an overall GVHD grade should be based on the organ stage, response to treatment 
and whether GVHD was a major cause of death.  
 
Overall 
Grade   Organ Stage  Qualifying Conditions  Additional Qualifying Conditions  
I Stage 1 -2 skin  No liver or gut  Indicates that the prophylactic 
immunosuppressive regimen was not 
sufficient to prevent all manifestations of 
aGVHD.  
II Stage 3 skin  
 or  
Stage 1 liver  
 or  
Stage 1 gut  N/A Indicates that the prophylactic 
immunosuppressive regimen was not 
sufficient to prevent all manifestations of 
aGVHD, but glucocorticoid treatment after 
the onset of GVHD was generally sufficient 
to control the disease.  
III Stage 4 skin  
 or  
Stage 2 -4 liver  
 or  
Stage 2 -4 gut   
without  GVHD as a major 
contributing cause of death  
 
 Indicates that the prophylactic 
immunosuppressive regimen was not 
sufficient to prevent all manifestations of 
aGVHD and that additional treatment after 
the onset of GVHD did not readily control 
the disease.  
IV Stage 4 skin  
 or  
Stage 2 -4 liver  
 or  
Stage 2 -4 gut   
with GVHD as a major 
contributing cause of death  
 
 GVHD was resistant to both the prophylactic 
immunosuppressive regimen and any 
additional treatment after the onset of the 
disease.  
 
References:  
 
1. Leisenring, WM, Martin, PJ, Petersdorf, EW, et al. An acute graft -versus -host-disease activity 
index to predict survival after hematopoietic cell transpl antation with myeloablative conditioning 
regimens, Blood, 2006:108: 749 -755. 
2. Przepiorka D, Weisdorf D, Martin PJ, et al. 1994 Consensus Conference on Acute GVHD 
Grading. Bone Marrow Transplant. 1995:15: 825 -828. 
 
 
 
 
 
 
 
 
2546.00  - Nonablative  
62 
FHCRC Current Version:  02/06/2018  
 
 APPENDIX  D 
GVHD Assessment Form  
 
GVHD assessment 
form.pdf
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2546.00  - Nonablative  
63 
FHCRC Current Version:  02/06/2018  
 
 APPENDIX  E 
 
Evaluation of Disease Response  
 
Chronic myeloid Leukemia (CML)  
Complete response:  Normalization of the WBC  with complete disappearance of the Ph 
chromosome in 20/20 metaphases whenever possible. Molecular response is 
defined by negative RT -PCR for the BCR/ABL transcripts in bone marrow or 
blood.  
Partial response:  Normalization of the white count with >0% but ≤35% Ph -metaphases.  
No response:  Persistence of ≥80% Ph -positive metaphases.  
Progressive disease:  Acquisition of a new cytogenetic abnormality and/or development of 
accelerated phase or blast crisis. The criteria for accelerated phase will be 
defined as unexplained fever greater than 38.3° C, new clonal cytogenetic 
abnormalities in addition to a single Ph -positive chromosome, marrow blasts 
and promyelocytes >20%.  
 
Acute leukemia (AML, ALL)  
Complete response:  <5% marrow blasts by pathology and no circulat ing leukemic blasts.  
Partial response:  5-30% marrow blasts, or <5% marrow blasts with circulating blasts.  
Stable disease:  >30% marrow blasts without definite deterioration of performance status or 
worsening of anemia, neutropenia, or thrombocytopenia.  
Progressive disease:   
 Evidence of relapse (>5% blasts) by morphologic or flow cytometric evaluation 
of the bone marrow aspirate or appearance of extramedullary disease.  
 
Chronic lymphocytic leukemia (CLL)  
Complete remission:  Normal imaging studies (X -ray, CT, MRI) (nodes, liver, and spleen), peripheral 
blood by flow cytometry has no clonal lymphocytes, bone marrow by flow 
cytometry has no clonal lymphocytes, bone marrow by morphology has no 
nodules (or if present, nodules are free from CLL cells by  
immunohistochemistry), and the duration is ≥2 months.  
CR with minimal  Peripheral blood or bone marrow by flow cytometry >0 - <1 CLL  
residual disease:  cells/1000  leukocytes (0.1%)  
 
Partial remission:  Absolute lymphocyte count in peripheral blood ≥50% decrease3 and physical 
exam/Imaging studies (nodes, liver, and/or spleen) ≥50% decrease3, 4. 
Duration is ≥2 months.  
Progressive disease:  ≥1 of: Physical exam/imaging studies (nodes, liver, and/or spleen) ≥50% 
increase or new, circulating lymphocytes by morphology and/or flow cytometry 
≥50% increase, and lymph node biopsy with Richter’s transformation  
Stable disease:  Did not meet any of the above criteria for complete or partial remission or 
progression.  
Relapsed disease:  Criteria of progression occurring 6 months after achievement of complete or 
partial remission.  
 
 
Lymphoma [Hodgkin's Disease, Non -Hodgkin's Lymphoma (NHL)]  
Complete respons e:  Disappearance of all clinically detectable disease.  
Partial response:  ≥50% reduction of the sum of the products of the perpendicular diameters of 
marker lesions, no progression of any existing lesions, and no new lesions.  
Stable disease:  Stabilizatio n of all existing lesions with no new lesions (i.e. a <25% increase 
or <50% decrease in disease parameters defined above throughout the 
treatment period).  
2546.00  - Nonablative  
64 
FHCRC Current Version:  02/06/2018  
 
 Progressive disease:  >25% increase in the sum of the products of the perpendicular diameters of 
marker lesions, or the appearance of new lesions.  
 
Multiple Myeloma (MM)  
Complete response:  Disappearance of plasmacytomas; decrease in marrow plasmacytosis to 
<10%; ≥75% reduction of the monoclonal serum protein. Reduction of the 24 
hour uri ne M -component to ≤10% of the initial prestudy value and to less than 
0.2 g/day; no increase in the size or number of lytic skeletal lesions; and 
normal serum calcium.  
Partial response:  ≥50%, <75% reduction of the monoclonal serum protein and reduction of the 
24 hour urine M -component to <0.2 g m/day; no increase in serum calcium, or 
in the size or number of plasmacytomas or lytic skeletal lesions.  
Stable disease:  <50% reduction or <100% increase of the serum myeloma protein.  
Progressive Diseas e:  ≥100% increase of the serum myeloma protein from its lowest level, or 
reappearance of myeloma peaks that had disappeared with treatment; or 
definite increase in the size or number of plasmacytomas or lytic bone lesions.  
Myelodysplasia  (MDS) 
Progressive Disease:  Any evidence by morphologic or flow cytometric evaluation of the bone 
marrow aspirate of new blasts (>5%).  
 
 
 
 
 
 
1 Without granulocyte colony stimulating factor support.  
2 Without red blood cell transfusions or erythropoietin support.  
3 Compared to before starting therapy.  
4 Defined by the sum of the products of up to 6 lymph nodes with no increase in the size of any single lymph node (ie, an incre ase of <25 percent 
in a lymph node <2cm is not considered significant) and no new enlarged lymph nodes. 
 
1.  Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR.  National Cancer Institute -
sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for 
diagnosis and treatment.  Blood 87: 49 90-4997, 1996.  
  2.   Hallek M, Cheson BD, Catovsky D, Caligaris -Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, 
Montserrat E, Rai KR, Kipps TJ, International Workshop on Chronic Lymphocytic Leukemia.  
Guidelines for the diagnosis and treatment of c hronic lymphocytic leukemia: a report from the 
International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute -
Working Group 1996 guidelines [Erratum appears in Blood. 2008 Dec 15;112(13):5259].  Blood 
111: 5446 -5456, 2008.  
  3.   Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. International 
Workshop on Chronic Lymphocytic Leukemia.  Ann Intern Med 110: 236 -238, 1989.  
 
 
 
 
 
 
 
 
 
 
 
 
2546.00  - Nonablative  
65 
FHCRC Current Version:  02/06/2018  
 
 APPENDIX F 
 
Study Coordinator’s Manual  
 
I. Introduction  
The mixed chimerism protocols have been opened to multiple sites to increase the referral base and 
accrual. Because of this expansion of collaborators, the data collection procedures are being revised. The 
procedure manual was created to assur e consistency of data reporting across the centers and to assure 
compliance with regulations. General expectations of collaborators are that they will comply with 
appropriate regulatory requirements, specified protocol requirements, and provide outcome dat a. 
 
The manual translates working procedures for study coordination. Its goal is to describe the procedures 
with sufficient clarity to ensure that all study centers will use the same procedures and follow -up 
schedules for participant data management and re porting. Changes to the manual and relevant forms will 
be made as soon as practical and will become effective on receipt of the revised procedures at the study 
centers, unless otherwise noticed.  
 
II. Institutional Review Board Review of Protocols and Modifications  
All research protocols proposed for use that involves human subjects must be reviewed and approved by 
the Institutional Review Board (IRB) prior to implementation. New protocols will undergo review at the 
FHCRC IRB and then will be distribute d to sites that wish to participate for their IRB’s review. For Centers 
that have a Federal Wide Assurance (FWA), formal collaboration includes submission of a form 310 and a 
copy of the IRB approved protocol and consent forms to the FHCRC.  For sites with out a FWA, an FWA 
form needs to be filed. Once the paperwork is submitted to the Office for Human Research Protection, the 
approval process can take up to a couple of months, and must be completed  before collaboration on a 
protocol can begin.  
 
In addition,  all amendments and/or revisions to on -going, approved activities must be submitted for review 
and approved prior to implementation  at an institution.  No revisions may be implemented at outside 
institutions without the prior approval of the FHCRC Principa l Investigator.   The FHCRC and the local 
site’s IRB must review all protocol activities at least once annually. This must be done within 365 days of 
the last review. A copy of annual renewal approvals must be received for collaboration to continue for the  
next year.  
 
III. Registrations  
Collaborating Institutions : The principal investigator of the collaborating institution who will register the 
patient with the FHCRC will identify eligible patients. Registration will include completion of the eligibility 
checkli st/demographic form. This form will be faxed (206 -667-5378) prior to treatment initiation. Patients 
should be registered prior to treatment initiation for valid registration  
 
IV. Reporting Adverse Events  
The following guidelines are the minimum serious adverse  event (SAE) reporting guidelines for Category 
1 and 2 studies conducted at the Fred Hutchinson Cancer Research Center.   
 
Expedited Reporting Requirements   
All adverse events (whether occurring on -site or off -site), which in the opinion of the 
principal investigator are (1) unexpected , and (2)  related or possibly related to the 
research and (3) serious or suggests that the research places research participant s or 
others at a greater risk of physical or psychological harm than was previously known or 
recognized must be submitted to the IRB within ten (10) calendar days of becoming 
aware of the event.  
 
 
 
2546.00  - Nonablative  
66 
FHCRC Current Version:  02/06/2018  
 
 Definitions  
 
An Adverse Event  - Any untoward medical occur rence in a patient or clinical investigation subject 
administered a pharmaceutical product, medical treatment or procedure and which does not necessarily 
have to have a causal relationship with this treatment.  An adverse event can therefore be any 
unfavor able and unintended sign (including an abnormal laboratory finding, for example), symptom, or 
disease temporally associated with the use of a medicinal product, medical treatment or procedure 
whether or not considered related  to the medicinal product .  
 
Related or Possibly Related Adverse Event:  An adverse event is “related or possibly related to 
the research procedure” if in the opinion of the principal investigator, it was more likely than not caused by 
the research procedures. Adverse events that are solely  caused by an underlying disease, disorder or 
condition of the subject or by other circumstances unrelated to either the research or any underlying 
disease, disorder or condition of the subject are not “related or possibly related.” If there is any q uestion 
whether or not an adverse event is related or possibly related, the adverse event should be reported.   
 
Serious Adverse Event: An adverse event that results in any of the following outcomes:  
▪ death  
▪ a life -threatening adverse event (real risk of dying)  
▪ unplanned inpatient hospitalization or prolongation of existing hospitalization  
▪ a persistent or significant disability/incapacity /or change in psychosocial status  
▪ a congenital anomaly  
▪ requires intervention to prevent permanent impairment of damage  
 
o Life-threatening AE  is defined as any adverse event that places the patient or subject, in view 
of the investigator, at immediate risk of  death from the reaction.  
 
Unexpected Adverse Event: An adverse event is “unexpected” when its nature (specificity), severity, 
or frequency are not consistent with (a) the known or foreseeable risk of adverse events associated with 
the research procedures  described in the protocol -related documents, such as the IRB -approved 
research protocol, informed consent document and other relevant sources of information such as product 
labeling and package inserts; and are also not consistent with (b) the characteris tics of the subject 
population being studied including the expected natural progression of any underlying disease, disorder 
or condition or any predisposing risk factor profile for the adverse event.  
 
To ensure no confusion or misunderstanding exist of th e differences between the terms “serious” and 
“severe,” which are not synonymous the following note of clarification is provided:  
 
The term “severe” is often used to describe the intensity (severity) or a specific event (as in mild, 
moderate or severe myoc ardial infarction); the event itself, however, may be of relatively minor medical 
significance (such as severe headache).  This is not the same as “serious,” which is based on 
patient/event outcome or action  criteria usually associated with events that pos e a threat to a patient’s life 
or functioning.  Seriousness (not severity) serves as a guide for defining regulatory obligations.  
 
For example, hospitalization, in general, will not be considered a serious adverse event as approximately 
half of evaluable M RD patients AND the majority of evaluable URD patients receiving non -myeloablative 
transplants were hospitalized.  Hospitalization will be considered a serious adverse event if it fulfills the 
criteria for a serious and unexpected adverse event as describe d above.  
 
Serious events, including deaths, due to GVHD and/or infections will not be reported on an expedited 
basis.  These are well documented, expected, post transplant complications and will be reported 
biannually to the DSMB.  
 
2546.00  - Nonablative  
67 
FHCRC Current Version:  02/06/2018  
 
 FHCRC is acting as the Coordinating Center for this multi -institutional study, and it is the responsibility of 
the FHCRC Principal Investigator (or designee) to complete the FHCRC Serious Adverse Event Report 
for all serious adverse events that meet the expedited reporting r equirements that are received from the 
participating sites. It is the responsibility of the FHCRC Principal Investigator to notify the sponsor, NIH, 
FDA or other agencies of serious adverse events as required in the protocol.  
 
Procedure for Reporting Serio us and Unexpected Adverse Events (SAE) from 
Participating Sites : Regulations defining the responsibilities for reporting serious and unexpected 
adverse reactions are defined above.  
 
Donor : SAEs or any death regardless of cause (serious, unexpected, and related/possibly related) will 
be monitored and recorded from the time the donor starts atorvastatin therapy through 7 days after the 
discontinuation of the medication . These must be reported  to the FHCRC Investigator within 10 days of 
learning of the event.  
 
Recipient : SAEs (life -threatening or fatal)   
• For 2546 as an adjunct to treatment plan or primary protocol , SAEs or any death 
regardless of cause (serious, unexpected, and related/possibly related)  will be monitored and 
recorded from the time the recipient starts conditioning therapy through day 100 or discharge 
from the center, whichever occurs earlier.  These must be reported to the FHCRC Investigator 
within 10 days of lear ning of the event.  
• For 2546 as an adjunct to a nonmyelo ablative investigational protocol , follow 
reporting guidelines of nonmyelo ablative investigational protocol.  
 
The immediate telephone report must be followed by faxed comments to the FHCRC Trial Coord inator at 
(206) 667 -5378. This will be followed by detailed written report (See Appendix G) within 10 working days.  
The report must include the date and time of onset, severity and duration of the event, the relationship to 
the study, the treatment given and eventual outcome.  Follow -up information to a SAE report must be 
submitted as soon as the relevant information is available.   
 
 
Reporting of Adverse Events on Case Report Forms (CRF)  
All grade 3 or 4 adverse events (or highly unusual g rade 2 adverse eve nts), which occur between start of 
conditioning and day 100 during the study will be recorded on the CRF .  These adverse events which are 
observed by the Investigator or reported by the patient, whether or not attributed to the study, wil l be 
reported on the Case Report Form using the selected (for this protocol) NCI Common Toxicity Criteria 
(NCI-CTC) version 4 ( Appendix J). Attributes will include a description, date of onset, maximum severity, 
and assessment of relationship to the study agent or other suspect agent(s). These grade 3 or 4 adverse 
events will be reported to the DSMB as part of the biannual review of the protocol. The DSMB report is 
submitted with the annual IRB renewal.  
 
For 2546 adjunct to a treatment plan (FHCRC or Outsid e Center)  
Only SAEs (life -threatening or fatal) will be captured on SAE form (Appendix G). No other grade 3 or 4 
Adverse Events will be captured.  
 
Reporting of Unanticipated Problems that Involve Risk to Research Participants or 
Others:  Any incident, experience, or outcome that meets both of the following criteria:  
• Unexpected (in terms of nature [specificity], severity, or frequency) given (a) the research 
procedures that are described in the protocol -related documents, such as the IRB -approved 
research protocol and informed consent document; and (b) the characteristics of the subject 
population being studied;  
2546.00  - Nonablative  
68 
FHCRC Current Version:  02/06/2018  
 
 • Indicates that the research places research participants or others at a greater risk of harm 
(including physical, psychological, e conomic, or social harm) than was previously known or 
recognized.  
 
These must be reported to the FHCRC Investigator within 10 days of learning of the event as described 
above for reporting of SAE.  
 
V. Case Report Forms  
 
Donor  CRFs  – safety evaluations at three timepoints (CRFs to be provided to external sites)  
(Appendix M)  
• Prior to start of statins  
• First day of collection  
• 7 days post collection  
 
Recipient  CRFs   
 
For 2546 as an adjunct to treatment plan or primary protocol   
• Acute GVHD grading form at approximately Day 100  (Appendix  D) 
• Patient status on an ongoing basis  
 
For 2546 as an adjunct to a nonmyeloblative investigational protocol  
• Follow CRF guidelines and instructions of nonmyeloblative investigational protocol.  
 
VI. Protocol Monitoring  
The guidelines below are intended to guide the reviewers in their assessment of items that significantly 
alter the clinical effectiveness of the treatment or the evaluation of its toxicity.  
 
A. Registration/Randomization  
1. Patient  was registered prior to treatment and approval by FHCRC PI occurs prior to 
randomization.  
2. Information given at registration represents actual data in medical records (stage, diagnosis, cell 
type, etc.)  
 
B. Informed Consent/IRB Approval Dates  
1. The consent was  signed prior to registration  
2. The consent is in language was approved by the IRB. IRB approval and reapproval are 
documented including appropriate use of full -board review and proper review of appropriate 
amendments or revisions  
3. Consent was dated and has w ritten witness signature. IRB approval was obtained prior to the 
patient signing the consent form and start of treatment.  
 
C. Patient Eligibility  
1. Eligibility criteria and exclusion criteria were met  
2. Treatment/Intervention Administration  
3. Doses were modified ac cording to protocol  
4. Accurate documentation of drug administration  
 
D. Study Tests/Evaluation  
1. Protocol specified laboratory tests or diagnostic studies are available  
2. Appropriate record of protocol intervention is documented.  
 
E. Study Events/Adverse Drug Experience  
1. Serious Adverse Evens reported according to protocol specifications  
2546.00  - Nonablative  
69 
FHCRC Current Version:  02/06/2018  
 
  
F. Follow -Up 
1. Disease status assessed according to the required protocol guidelines documenting response to 
treatment.  
2. Accurate determination of cancer progression  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2546.00  - Nonablative  
70 
FHCRC Current Version:  02/06/2018  
 
 APPENDIX G 
Serious Adverse Event Report  
Protocol  2546  
 
 
1. Patient’s Name:   
 
2. Date of Serious Adverse Event:    
 
3. Nature of Serious Adverse Event:   
 
4. Reasons for AE classification as serious: (mark all that apply)  
 
   Death      Urgent medical intervention to prevent death or  
   New hospitalization           disability  
     Prolongation of current hospitalization      New persistent or exacerbation of significant  
              disability or incapacity  
     
5. Specify any agent(s) suspected of causing adverse event:  
 
#1    
                                  
6. Describe the Serious Adverse Event (or attach a copy of relevant medical records or FDA MedWatch 
Form) . 
 
7. Signature of Reporter ______________________________________________ /___/________  
          Date  
8. PI assessment  
 
Adverse event possibly, probably or definitely related to investigational agent(s)?  ○No   ○Yes  
Adverse event    ○expected   ○unexpected (not listed in protocol, consent, product label or drug 
brochure)  
Expedited report to FHCRC IRB is needed if serious a dverse event is unexpected and related to 
investigational agent.  
 
9. Signature of P.I. ______________________________________________ /___/____________  
                                                                                 Date  
 
  
2546.00  - Nonablative  
71 
FHCRC Current Version:  02/06/2018  
 
 APPENDIX H 
Notice of Death  
 
 
Patient ID:  __________________  Date of Death:  ______________  
 
Place of Event:  ___________________________________________    
 
 
Apparent cause of death (Please be specific.  Attach hospital summary or death summary when 
possible):  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Form completed by:  ________________________________Date:   ______________  
 
 
 
 
 
 
2546.00  - Nonablative  
72 
FHCRC Current Version:  02/06/2018  
 
  
APPENDIX  I 
 
COORDINATING CENTER FUNCTIONS  
 
Outside Center – PI Communication in Hematologic Malignancies  
 
I. Study Management, data analysis, and Data and Safety Monitoring  
 a. Study Management:  
i. Each local PI is responsible for selection, training and oversight of local study 
coordinators  
ii. The Coordinating Center registers subjects on the study and assigns study IDs  
iii. One copy of the research data is retained by the site. Another data set (identified 
only by study IDs) is transmitted to the Coordinating Center to create the master data 
file. All data are kept in locked areas and password protected databases accessible 
only to study staff  
iv. The quality of data is monitored in an ongoing fashion with the study team and 
corrective action plans instituted as necessary  
b. Data Analysis:  
i. Study staff review data for completeness as it is submitted by the sites  
ii. The study statistician is responsible for data cleaning and the conduct of analyses as 
outlined in the protocol and grant  
c. Data Safety and Monitoring:  
i. The trial coordinators at collaborating centers or the local PIs will fax an official report 
of an SAE (as define d by the protocol) to the Coordinating Center within ten days.  
ii. The SAE report is reviewed by the Overall PI. If the SAE meets the FHCRC criteria 
for reporting then an official signed report is submitted to the IRB  
iii. An independent DSMB will meet at six -month  intervals and all outcome data is 
reviewed including all adverse events and SAEs reported to the Coordinating Center 
along with those officially reported to the IRB  
iv. A report from the DSMB is submitted to the IRB as well as the trial coordinators/local 
PIs participating in the protocol  
 
II.  Protocol and informed consent document management  
a. A master protocol is maintained by the Coordinating Center and distributed to the sites for 
customization and local IRB review  
b. All protocol and consent modifications ini tiated by the Coordinating Center are sent to the 
Collaborating Sites following approval by the Coordinating Center IRB, for review and 
approval by the local IRB  
c. Changes required by local IRBs are reviewed by the Coordinating Center and approved 
prior to i mplementation at local sites  
 
III. Assurance of local IRB OHRP -approved assurance  
a. Each site provides their OHRP assurance number and evidence of IRB certification  
b. Study staff monitor maintenance of institutional assurance and IRB certification  
 
 
IV. Assurance of local IRB approvals  
a. The Coordinating Center maintains copies of the most current collaborating site Consent 
Forms and IRB approval documentation  
b. No site may enroll subjects until the Coordinating Center has received confirmation of local 
IRB a pproval  
c. Each site is responsible for preparation and submission of their continuing reviews. Any 
changes to the protocol or consent form will be communicated to the Coordinating Center  
2546.00  - Nonablative  
73 
FHCRC Current Version:  02/06/2018  
 
 d. Sites are required to have active IRB approvals to participate in any s tudy related activities  
 
V. Any substantive modification by the Collaborating Institution related to risks or alternative 
procedures is appropriately justified  
a.   The Coordinating Center reviews any modifications to consent forms to ensure that site 
cons ents do not delete or change the basic or additional elements or alternatives required 
in the sample consent form  
 
VI. Informed consent is obtained from each subject in compliance with HHS regulations  
a. Subjects must provide written informed consent prior to  study participation  
b. The Coordinating Center verifies eligibility and signed consent prior to assigning a study ID 
number  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2546.00  - Nonablative  
74 
FHCRC Current Version:  02/06/2018  
 
 APPENDIX J 
Adapted from  
COMMON TOXICITY CRITERIA (CTC)  
Version 4.0  
 
 
Grade  
Adverse Event  3 4 5 
 
BLOOD AND LYMPHATIC SYSTEM DISORDERS  
 
Disseminated intravascular 
coagulation  Laboratory findings and 
bleeding  Life-threatening 
consequences; urgent 
intervention indicated  Death  
Febrile neutropenia  ANC <1000/mm3 with a 
single temperature of 
>38.3 degrees C (101 
degrees F) or a sustained 
temperature of >=38 
degrees C (100.4 degrees 
F) for more than one hour  Life-threatening 
consequences; urgent 
intervention indicated  Death  
Hemolysis  Transfusion or medical 
intervention indicated 
(e.g., steroids)  Life-threatening 
consequences; urgent 
intervention indicated  Death  
Hemolytic uremic syndrome  Laboratory findings with 
clinical consequences (e.g., 
renal insufficiency, 
petechiae)  Life-threatening 
consequences, (e.g., CNS 
hemorrhage or 
thrombosis/embolism or 
renal failure)  Death  
Grade  
Adverse Event  3 4 5 
 
CARDIAC DISORDERS  
 
Atrial fibrillation  Symptomatic and 
incompletely controlled 
medically, or controlled 
with device (e.g., 
pacemaker), or ablation  Life-threatening 
consequences; urgent 
intervention indicated  Death  
Atrial flutter  Symptomatic and 
incompletely controlled 
medically, or controlled 
with device (e.g., 
pacemaker), or ablation  Life-threatening 
consequences; urgent 
intervention indicated  Death  
Atrioventricular block 
complete  Symptomatic and 
incompletely controlled 
medically, or controlled 
with device (e.g., 
pacemaker)  Life-threatening 
consequences; urgent 
intervention indicated  Death  
Constrictive pericarditis  Symptomatic heart failure 
or other cardiac symptoms, 
responsive to intervention  Refractory heart failure or 
other poorly controlled 
cardiac symptoms  Death  
2546.00  - Nonablative  
75 
FHCRC Current Version:  02/06/2018  
 
 Heart failure  Severe with symptoms at 
rest or with minimal 
activity or exertion; 
intervention indicated  Life-threatening 
consequences; urgent 
intervention indicated (e .g., 
continuous IV therapy or 
mechanical hemodynamic 
support)  Death  
Left ventricular systolic 
dysfunction  Symptomatic due to drop 
in ejection fraction 
responsive to intervention  Refractory or poorly 
controlled heart failure due 
to drop in ejection fractio n; 
intervention such as 
ventricular assist device, 
intravenous vasopressor 
support, or heart transplant 
indicated  Death  
Myocardial infarction  Severe symptoms; cardiac 
enzymes abnormal; 
hemodynamically stable; 
ECG changes consistent 
with infarction  Life-threatening 
consequences; 
hemodynamically unstable  Death  
Myocarditis  Severe with symptoms at 
rest or with minimal 
activity or exertion; 
intervention indicated  Life-threatening 
consequences; urgent 
intervention indicated (e.g., 
continuous I V therapy or 
mechanical hemodynamic 
support)  Death  
Pericardial effusion  Effusion with physiologic 
consequences  Life-threatening 
consequences; urgent 
intervention indicated  Death  
Pericardial tamponade   - Life-threatening 
consequences; urgent 
intervention indicated  Death  
Ventricular arrhythmia  Medical intervention 
indicated  Life-threatening 
consequences; 
hemodynamic compromise; 
urgent intervention 
indicated  Death  
Grade  
Adverse Event  3 4 5 
 
GASTROINTESTICAL DISORDERS  
 
Ascites  Severe symptoms; invasive 
intervention indicated  Life-threatening 
consequences; urgent 
operative intervention 
indicated  Death  
Diarrhea  Increase of >=7 stools per 
day over baseline; 
incontinence; 
hospitalization indicated; 
severe increase in ostomy 
output compared to 
baseline; limiting self care 
ADL  Life-threatening 
consequences; urgent 
intervention indicated  Death  
2546.00  - Nonablative  
76 
FHCRC Current Version:  02/06/2018  
 
 Duodenal ulcer  Severely altered GI 
function; TPN indicated; 
elective operative or 
endoscopic intervention 
indicated; limiting self care 
ADL; disabling  Life-threatening 
consequences; urgent 
operative intervention 
indicated  Death  
Gastric ulcer  Severely altered GI 
function; TPN indicated; 
elective operative or 
endoscopic intervention 
indicated; limiting self care 
ADL; disabling  Life-threatening 
consequences; u rgent 
operative intervention 
indicated  Death  
Gastritis  Severely altered eating or 
gastric function; TPN or 
hospitalization indicated  Life-threatening 
consequences; urgent 
operative intervention 
indicated  Death  
Lower gastrointestinal 
hemorrhage  Transfusion, radiologic, 
endoscopic, or elective 
operative intervention 
indicated  Life-threatening 
consequences; urgent 
intervention indicated  Death  
Mucositis oral  Severe pain; interfering 
with oral intake  Life-threatening 
consequences; urgent 
interventio n indicated  Death  
Oral hemorrhage  Transfusion, radiologic, 
endoscopic, or elective 
operative intervention 
indicated  Life-threatening 
consequences; urgent 
intervention indicated  Death  
Pancreatitis  Severe pain; vomiting; 
medical intervention 
indicated (e.g ., analgesia, 
nutritional support)  Life-threatening 
consequences; urgent 
intervention indicated  Death  
Typhlitis  Symptomatic (e.g., 
abdominal pain, fever, 
change in bowel habits 
with ileus); peritoneal 
signs  Life-threatening 
consequences; urgent 
operative intervention 
indicated  Death  
Grade  
Adverse Event  3 4 5 
 
GENERAL DISORDERS AND ADMINISTARTION SITE CONDITIONS  
 
Multi -organ failure  Shock with azotemia and 
acid-base disturbances; 
significant coagulation 
abnormalities  Life-threatening 
consequences (e.g., 
vasopressor dependent and 
oliguric or anuric or 
ischemic colitis or lactic 
acidosis)  Death  
Grade  
Adverse Event  3 4 5 
 
HEPATOBILIARY DISORDERS  
 
2546.00  - Nonablative  
77 
FHCRC Current Version:  02/06/2018  
 
 Cholecystitis  Severe symptoms; 
radiologic, endoscopic or 
elective operative 
intervention indicated  Life-threatening 
consequences; urgent 
operative intervention 
indicated  Death  
Grade  
Adverse Event  3 4 5 
 
IMMUNE SYSTEM DISORDERS  
 
Allergic reaction  Prolonged (e.g., not rapidly 
responsive to symptomatic 
medication and/or brief 
interruption of infusion); 
recurrence of symptoms 
following initial 
improvement; 
hospitalization indicated 
for clinical sequelae (e.g., 
renal impairment, 
pulmonary infiltrates)  Life-threatening 
consequences; urgent 
intervention indicated  Death  
Immune system disorders - 
Other, specify  Severe or medically 
significant but not 
immediately life -
threatening; hospitalization 
or prolongation of existing 
hospitalization indicated; 
disabling;  limiting self 
care ADL  Life-threatening 
consequences; urgent 
intervention indicated  Death  
Grade  
Adverse Event  3 4 5 
 
INFECTIONS AND INFESTATIONS  
 
Enterocolitis infectious  IV antibiotic, antifungal, or 
antiviral intervention 
indicated; radiologic, 
endoscopic, or operative 
intervention indicated; 
profuse watery diarrhea 
with signs of hypovolemia;  
bloody diarrhea; fever; 
severe abdominal pain; 
hospitalization indicated  Life-threatening 
consequences; urgent 
intervention indicated  Death  
Infections and infestations - 
Other, specify  Severe or medically 
significant but not 
immediately life -
threatening; hospitalization 
or prolongation of existing 
hospitalization indicated; 
disabling; limiting self care 
ADL  Life-threatening 
consequences; urgent 
intervention indicated  Death  
Grade  
Adverse Event  3 4 5 
2546.00  - Nonablative  
78 
FHCRC Current Version:  02/06/2018  
 
  
INVESTIGATIONS  
 
Alanine aminotransferase 
increased  >5.0 - 20.0 x ULN  >20.0 x ULN   - 
Aspartate aminotransferase 
increased  >5.0 - 20.0 x ULN  >20.0 x ULN   - 
Blood bilirubin increased  >3.0 - 10.0 x ULN  >10.0 x ULN   - 
Carbon monoxide diffusing 
capacity decreased  Asymptomatic decrease  of 
>8 units drop;  >5 units 
drop along with the 
presence of pulmonary 
symptoms (e.g. , >Grade 2  
hypoxia or >Grade 2 or 
higher dyspnea)   -  - 
Cardiac troponin I increased  Levels consistent with 
myocardial infarction as 
defined by the 
manufacturer   -  - 
Cardiac troponin T 
increased  Levels consistent with 
myocardial infarction as 
defined by the 
manufacturer   -  - 
Creatinine increased  >3.0 baseline; >3.0 - 6.0 x 
ULN >6.0 x ULN   - 
Weight gain  >=20% from baseline   -  - 
Grade  
Adverse Event  3 4 5 
 
METABOLISM AND NUTRITIONAL DISORDERS  
 
Hypercalcemia  Corrected serum calcium 
of >12.5 - 13.5 mg/dL;>3.1 
- 3.4 mmol/L;  Ionized 
calcium  >1.6 - 1.8 
mmol/L; hospitalization 
indicated  Corrected serum calcium of 
>13.5 mg/dL; >3.4 mmol/L;  
Ionized calcium  >1.8 
mmol/L; life -threatening 
consequences  Death  
Hypertriglyceridemia  >500 mg/dL - 1000 mg/dL;  
>5.7 mmol/L - 11.4 
mmol/L  >1000 mg/dL; >11.4 
mmol/L;  life-threatening 
consequences  Death  
Hyperuricemia  >ULN - 10 mg/dL (0.59 
mmol/L) with physiologic 
consequences  >10 mg/dL; >0.59 mmol/L; 
life-threatening 
consequences  Death  
Tumor lysis syndrome  Present  Life-threatening 
consequences; urgent 
intervention ind icated  Death  
Grade  
Adverse Event  3 4 5 
 
NEOPLASMS BENIGN, MALIGNANT, AND UNSPECIFIED (INC CYSTS AND POLYPS)  
 
Treatment related secondary 
malignancy  Non life -threatening 
secondary malignancy  Acute life -threatening 
secondary malignancy; blast 
crisis in leukemia  Death  
Grade  
2546.00  - Nonablative  
79 
FHCRC Current Version:  02/06/2018  
 
 Adverse Event  3 4 5 
 
NERVOUS SYSTEM DISORDERS  
 
Dysarthria  Severe impairment of 
articulation or slurred 
speech   -  - 
Intracranial hemorrhage  Ventriculostomy, ICP 
monitoring, 
intraventricular 
thrombolysis, or operative 
intervention indicated  Life-threatening 
consequences; urgent 
intervention indicated  Death  
Ischemia cerebrovascular   -  -  - 
Leukoencephalopathy  Severe symptoms; 
extensive T2/FLAIR 
hyperintensities, involving 
periventricular white 
matter involvi ng 2/3 or 
more of susceptible areas 
of cerebrum +/ - moderate 
to severe increase in SAS 
and/or moderate to severe 
ventriculomegaly  Life-threatening 
consequences; extensive 
T2/FLAIR hyperintensities, 
involving periventricular 
white matter involving most 
of susceptible areas of 
cerebrum +/ - moderate to 
severe increase in SAS 
and/or moderate to severe 
ventriculomegaly  Death  
Seizure  Multiple seizures despite 
medical intervention  Life-threatening; prolonged 
repetitive seizures  Death  
Syncope  Fainting; orthostatic 
collapse   -  - 
Nervous system disorders - 
Other, specify  Severe or medically 
significant but not 
immediately life -
threatening; hospitalization 
or prolongation of existing 
hospitalization indicated; 
disabling;  limiting self 
care ADL  Life-threa tening 
consequences; urgent 
intervention indicated  Death  
Grade  
Adverse Event  3 4 5 
 
RENAL AND URINARY DISORDERS  
 
Chronic kidney disease  eGFR or CrCl 29 - 15 
ml/min/1.73 m2  eGFR or CrCl <15 
ml/min/1.73 m2; dialysis or 
renal transplant indicated  Death  
Renal and urinary disorders 
- Other, specify  Severe or medically 
significant but not 
immediately life -
threatening; hospitalization 
or prolongation of existing 
hospitalization indicated; 
disabling;  limiting self 
care ADL  Life-threatening 
consequences; urgent 
intervention indicated  Death  
Grade  
Adverse Event  3 4 5 
2546.00  - Nonablative  
80 
FHCRC Current Version:  02/06/2018  
 
  
REPRODUCTIVE SYSTEM AND BREAST DISORDERS  
 
Grade  
Adverse Event  3 4 5 
 
RESPIRATORY, THORACIC, AND MEDIASTINAL DISORDERS  
 
Adult respiratory distress 
syndrome  Present with radiologic 
findings; intubation not 
indicated  Life-threatening respiratory 
or hemodynamic 
compromise; intubation or 
urgent intervention 
indicated  Death  
Apnea  Present; medical 
intervention indicated  Life-threatening respiratory 
or hem odynamic 
compromise; intubation or 
urgent intervention 
indicated  Death  
Bronchopulmonary 
hemorrhage  Transfusion, radiologic, 
endoscopic, or operative 
intervention indicated 
(e.g., hemostasis of 
bleeding site)  Life-threatening respiratory 
or hemodynamic 
compromise; intubation or 
urgent intervention 
indicated  Death  
Hypoxia  Decreased oxygen 
saturation at rest (e.g., 
pulse oximeter <88% or 
PaO2 <=55 mm Hg)  Life-threatening airway 
compromise; urgent 
intervention indicated (e.g., 
tracheotomy or in tubation)  Death  
Pleural effusion  Symptomatic with 
respiratory distress and 
hypoxia; surgical 
intervention including 
chest tube or pleurodesis 
indicated  Life-threatening respiratory 
or hemodynamic 
compromise; intubation or 
urgent intervention 
indicated  Death 
Pneumonitis  Severe symptoms; limiting 
self care ADL; oxygen 
indicated  Life-threatening respiratory 
compromise; urgent 
intervention indicated (e.g., 
tracheotomy or intubation)  Death  
Pulmonary edema  Severe dyspnea or dyspnea 
at rest; oxygen indicated; 
limiting self care ADL  Life-threatening respiratory 
compromise; urgent 
intervention or intubation 
with ventilatory support 
indicated  Death  
Respiratory failure   - Life-threatening 
consequences; urgent 
intervention, intubation, or 
ventilatory sup port 
indicated  Death  
Grade  
Adverse Event  3 4 5 
 
SKIN AND SUBCUTANEOUS TISSUE DISORDERS  
 
2546.00  - Nonablative  
81 
FHCRC Current Version:  02/06/2018  
 
 Erythema multiforme  Target lesions covering 
>30% BSA and associated 
with oral or genital 
erosions  Target lesions covering 
>30% BSA; associated with 
fluid or electrolyte 
abnormalities; ICU care or 
burn unit indicated  Death  
Grade  
Adverse Event  3 4 5 
 
VASCULAR DISORDERS  
 
Capillary leak syndrome  Severe symptoms; 
intervention indicated  Life-threatening 
consequences; urgent 
intervention indicated  Death  
Hypotension  Medical intervention or 
hospitalization indicated  Life-threatening and urgent 
intervention indicated  Death  
Thromboembolic event  Thrombosis (e.g., 
uncomplicated pulmonary 
embolism [venous], non -
embolic cardiac mural 
[arterial] thrombus), 
medica l intervention 
indicated  Life-threatening (e.g., 
pulmonary embolism, 
cerebrovascular event, 
arterial insufficiency); 
hemodynamic or neurologic 
instability; urgent 
intervention indicated  Death  
Vasculitis  Severe symptoms, medical 
intervention indicated 
(e.g., steroids)  Life-threatening; evidence 
of peripheral or visceral 
ischemia; urgent 
intervention indicated  Death  
 
 
 
  
2546.00  - Nonablative  
82 
FHCRC Current Version:  02/06/2018  
 
 APPENDIX  K 
Protocol 2546 Patient Demographics and Eligibility Form  
 
 
UPN#:____________________  
Patient Name:  _______________________________  
(Last)  ________________________  
(First)  _____  
(MI) 
Date of 
Birth:  _____ / _____ / __________  Age:________  
 (Mo)    (Day)         (Year)  Gender  (choose one):  
 Male     Female    Unknown  
Patient Diagnosis: 
______________________________________   Planned Day 0: _____/______/_____  
 (Mo) (Day)   (Year)  
Ethnicity  (choose one ):  Instruct the patient to select one  of the following.  
 Hispanic  (A person of Cuban, Mexican, Puerto Rican, South or Central American, or other 
Spanish culture or origin, regardless of race.  Term “Spanish Origin” can also be used in 
addition to “Hisp anic” or “Latino”.)  
 Not Hispanic or Latino  
  Declined to Report  
Race  (check all that apply ):  Instruct the patient to select one or more  of the following.  
 American Indian/Alaska Native  (A person having origins in any of the original peoples of 
North, Central, or South America, and who maintains tribal affiliations or community 
attachment).  
 Asian  (A person having origins in any of the original peoples of the Far East, Southeast, 
Asia, or the Indian subcontinent including, for example, Cambodia, China, I ndia, Japan, 
Korea, Malaysia, Pakistan, the Philippine Islands, Thailand and Vietnam).  
          Black/African American (A person having origins in any of the black racial groups of  
               Africa ).      
 Native Hawaiian/Pacific Islander  (A person having origins in any of the original peoples of 
Hawaii, Guam, Samoa or other Pacific Islands).  
 White  (A person having origins in any of the original peoples of Europe, the Middle East or 
North Africa).  
 Research subject does not know race  
 Declined to report  
 
 
 
The PI confirmed that patient should receive Fludarabine and TBI (If no autologous 
transplant within 6 months  or equivalent high -dose therapy without HCT ). 
 
Yes        No       Date:    ____________   PI Initials:  _____   
2546.00  - Nonablative  
83 
FHCRC Current Version:  02/06/2018  
 
  
 
CRITERIA FOR 3 GY TBI  (only for patients in Regimen A, Flu/TBI) : Patients need to fulfill 
one or more of the following criteria for 3 Gy TBI:  
 
 Patients with MDS,  MPD, CML, or other  hematologic malignancies not previously 
treated with myelosuppressive chemotherapy  
Patients who have had a previous allogeneic transplant.  
Patients  who had a prior syngeneic transplant  without subsequent myelosuppressive 
chemotherapy.  
 Patients who have not ha d myelosuppressive chemotherapy within 3 -6 months of 
HCT may be at higher risk of rejection depending on treatment history and underlying 
diagnosis. Confirm TBI dose (2 vs 3 Gy) with PI.  
 
CRITERIA FOR  4 Gy TBI : 
 For outside centers only, 4 Gy TBI may be used when the protocol serves as adjunct 
to a reduced intensity treatment plan that includes 4 Gy TBI.  
 
 
TBI Dose:  
 TBI 2 Gy          
 OR 
 TBI 3 Gy:  
        OR    
 TBI 4 Gy:  
 
 
Signature of  Local Principal Investigator :                                                                Date:              
   
Transplant Center:   ___________________________________________________________  
 
Signature of FHCRC Principal Investigator :                                                              Date :   
   
      
Study UPN#: _____________________________  
 
 
 
2546.00  - Nonablative  
84 
FHCRC Current Version:  02/06/2018  
 
 APPENDIX K cont’d  
 
Protocol 2546  Eligibility  
 
  2546 is being used as an adjunct Protocol. Patient is enrolled on an investigational 
nonmyeloablative HCT protocol or a nonmyeloablative treatment plan with postgrafting 
CSP that does not use acu te GVHD as its primary endpoint . 
• Must meet following inclusion criteria  1 ONLY  
• Must meet following exclusion criteria 16-18 ONLY  
 
OR 
 
  Protocol 2546 serves as an independent primary treatment protocol  
• Must meet all following inclusion and exclusion criteria  
 
Inclusion Criteria :  
 
 
1) Yes  No  HLA-identical sibling donor :       
 
Patient       
A: ________  A:_________  C: _________  C: _________  B: _________  B: _________  
DRB1:  ___ ____ DRB1:__ _____  DQB1:_____ __ DQB1:__ _____    
Donor       
A: _________  A:_________  C: _________  C: _________  B: _________  B: _________  
DRB1:  ____ ___ DRB1:____ ___ DQB1:___ ____ DQB1:_____ __   
 
 
2) Yes  No   N/A   All children < 12 years must be discussed with the FHCRC PI 
(Marco Mielcarek, MD 206 -667-2827)  and by a relevant patient 
review committee, such as the FHCRC Patient Care Conference 
(PCC)  prior to registration.  
 
3) Yes  No    Patients must have either relapsed after previous high -dose 
chemotherapy and autologous or allogeneic HCT, or else be 
ineligible for such an approach due to age, failure to mobilize 
sufficient hematopoietic stem cells, medical comorbidities, or 
patient refusal   
 
4) Yes  No  Patients who refuse to be treated on a conventional autologous or 
allogeneic HCT protoc ol. 
 
 
 
 
I) One of the following criteria questions ( 5-15) must be marked “Yes” for the patient to enter 
on 2546 . (The following diseases will be permitted although other diagnoses can be 
2546.00  - Nonablative  
85 
FHCRC Current Version:  02/06/2018  
 
 considered if approved by PCC or the participating institution’s patient review committees 
and the principal investigator .) 
 
5) Yes  No  Aggressive non -Hodgkin lymphomas (NHL) and other histologies 
such as diffuse large B -cell NHL  – not eligible for autologous HCT, not 
eligible for high -dose allogeneic HCT, or after failed autologous HCT.  
 
6) Yes  No   Mantle Cell NHL - Diagnostic LP required pre -transplant  
 
7) Yes  No   Low grade NHL – with < 6 month duration of CR between courses of 
conventional therapy.  
 
8 Yes  No   CLL – must have either 1) failed to m eet NCI Working Group criteria or 
partial response after therapy with a regimen containing FLU (or another 
nucleoside  analog, ) or experience disease relapse within 12 months after 
completing therapy with a regimen containing FLU (or another nucleoside 
analog); 2) failed FLU -CY-Rituximab (FCR) combination chemotherapy at 
any time point; or 3) have “17p deletion” cytogenetic abnormality. Patients 
should have received induction chemotherapy but could be transplanted 
in 1st CR; or 4) Patients with a diagnosis o f CLL (or small lymphocytic 
lymphoma) that progresses to prolymphocytic leukemia (PLL), or patients 
with T-cell CLL or PLL  
 
     Describe which inclusion is specific for this 
patient: __________________________________________________________                  
                    
9) Yes  No   Hodgkin lymphoma  – must have received and failed frontline therapy.  
 
 
10) Yes  No   Multiple Myeloma  – must have received prior chemotherapy.  
Consolidation of chemotherapy by autografting prior to nonmyeloablative 
HCT is permitted.  
 
11) Yes  No  Acute Myeloid Leukemia (AML) – must have < 5% marrow blasts at the 
time of transplant.  
 
12) Yes  No  Acute Lymphocytic Leukemia (ALL)  – must have <5% marrow blasts at 
the time of transplant.  
 
13) Yes  No   Chronic Myeloid Leukemia (CML)  – Patients  will be accepted if they  
have shown intolerance to tyrosine kinase inhibitors  or are beyond CP1 
and if they have received previous myelosuppressive chemotherap y or 
HCT, and have <5% marrow blasts at time of transplant.   
 
14) Yes  No  Myelodysplasia (MDS)/Myeloproliferative Syndrome (MPS)  –must  
   have  <5% marrow blasts at time of transplant.   
 
15) Yes  No       Waldenstrom’s Macroglobulinemia  – must have failed 2 courses of 
therapy.  
 
 
2546.00  - Nonablative  
86 
FHCRC Current Version:  02/06/2018  
 
 II) Exclusion criteria:   
Each of the following questions must be marked “No” Or “NA” for the patient to enroll on 2 546. 
 
16) Yes  No   Patient will undergo  a myeloablative preparative regimen . 
 
17) Yes  No    Patient is participating in an investigational study that has acute GVHD as  
the primary endpoint  
 
18) Yes  No    The allogeneic PBSC donor has a contraindication to statin treatment.  
 
19) Yes  No     Patients eligible for and willing to receive potentially curative high  
     dose  chemotherapy and autologous HCT 
 
20) Yes  No      Organ dysfunction.  Please check yes if patient meets any of the  
following.  
        Yes  No  Cardiac:  ejection  fraction < 30 % on MUGA 
scan or cardio echo or active symptomatic 
coronary art ery disease.  Patients with cardiac 
disease should be evaluated with appropriate 
cardiac studies and/or cardiology consultation 
as clinically indicated.   
 
        Yes  No  Pulmonary:  DLCO < 40%, TLC <3 0%, FE V1 
<30% and/or  receiving supplementary 
continuous oxygen.  
 
   Yes  No  Liver function abnormalities :  Patients with 
clinical or labora tory evidence of liver disease 
should be evaluated  in conjunction with the GI 
consult service for  the cause of liver disease, its 
clinical severity, and the degree of portal 
hypertension.  Patients will be excluded if they 
are found to have fulminant liver failure, 
cirrhosis of the liver with evidence of portal 
hypertension,  bridging fibrosis,  alcoholic 
hepatitis, esophageal varices, a  history of 
bleeding esophageal va rices, hepatic 
encephalopathy, refractory ascites related to 
portal hypertension, bacterial or fungal liver 
abscess, chronic viral hepatitis with total serum 
bilirubin >3 mg/dL, or  actively symptomatic 
biliary disease.   
 
   Yes  No      Renal : Patients with renal failure are eligible. 
However, patients with pre -existing renal 
insufficiency will likely have further compromise 
in renal function and may require dialysis.  
 
21) Yes  No               Patients who are seropositive for human immunodeficiency  
          virus (HIV).  
 
2546.00  - Nonablative  
87 
FHCRC Current Version:  02/06/2018  
 
 22) Yes  No  N/A   Women who are pregnan t or breast -feeding.  
 
 
23) Yes  No  N/A   Fertile men or women unwilling to use contraception durin g HCT 
 and for 12 months afterward  
. 
24) Yes  No         Patients with active non -hematological malignancies (except non -
melanoma skin cancers) o r those with non -hematological malignancies 
(except non -melanoma skin cancers) who have been rendered with no 
evidence of disease, but have a greater than 20% chance of having 
disease recurrence within 5 years. This exclusion does not apply to 
patients wit h non -hematologic malignancies that do not require therapy.  
 
25) Yes  No  Karnofsky score <60 for adult patients  or Lansky -Play Performance Score 
<50 for pediatric patients.  
 
26) Yes  No  Patients with fungal pneumonia with radiological progression  after receipt 
of amphotericin formulat ion or mold -active azoles for greater than 1 
month  
 
Note – the HCT -Comorbidity score is:  _______________  
 
 
 
 FHCRC Patients:  
Signature of person completing form:                                            Date:    
 
Signature of Principal Investigator (signing of consent):                     Date:             
 
Patient signed IRB approved consent form.  Date:         
 
IRB file number:                           Date of IRB approval:    
 
OR 
 
Outside Center Patients:  
 
Signat ure of person completing form:          Date:    
 
Patient signed IRB approved consent form.    Date:       
 
IRB file number:                            Date of IRB approval:    
 
Signature of  Local  Principal Investigator        Date:    
 
Signature of FHCRC Principal Investigator                   Date:    
 
 
 
 
2546.00  - Nonablative  
88 
FHCRC Current Version:  02/06/2018  
 
 APPENDIX  L 
2546 Case Report Form  
 
 
2546 CRF v.1.0.pdf
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2546.00  - Nonablative  
89 
FHCRC Current Version:  02/06/2018  
 
 APPENDIX  M 
 
Protocol 2546 Donor Safety and Compliance Evaluation  
 
Date:  _______________       Donor:  __________________________  
Contact:  phone    in-person   Patient: ________________________  
 
Time point:  
___ 1 week post start of atorvastatin    
___ PBSC collection   
___ 1 week post collection/discharge  
 
Start date of atorvastatin: __________   Last dose (date):  ___________  
      
Total number of doses taken: ________  
Safety  
 
Since the start of atrovastatin therapy have you experienced any of the following symptoms:  
      Y    N  
  muscle pain or tenderness     Location:  _____________________________  
  muscle weakness     Location:  ____________________________________  
  joint pain     Location:  _________________________ _________________  
  diarrhea  
  gas or heartburn  
  nausea  
  other     Describe:  ______________________________________________  
 
Action/comments:  
 
 
 
Labs      Comments:  
Labs  Pre Post 
Date    
CK   
T Bili    
D Bili    
ALT   
AST   
Alk 
Phos    
Albumin    
 
Compliance  
Since the last contact, have you missed any doses of atorvastatin?  Yes No 
If yes, how many doses have been missed?  __________________  
 
Comments:  
 
 
   
Signature       Date  
 
 
2546.00  - Nonablative  
90 
FHCRC Current Version:  02/06/2018  
 
 APPENDIX  N 
(Not required when 2546 is being used as an adjunct Protocol)  
The Hematopoietic Cell Transplant -Comorbidity Index (HCT -CI) 9/7/10  
Assign scores appropriately if the patient has any of these comorbidities  
  
Patient ____________________________(name),   UPN______________ Date_____________  
 
 
Comorbidities  Definitions  HCT -CI 
scores  Actual Lab 
Values/Comments  
Arrhythmia  Atrial fibrillation or flutter, sick sinus syndrome, and 
ventricular arrhythmias requiring treatment in the patient’s 
past history  1  
Cardiac  Coronary artery disease†, congestive heart failure, 
myocardial infarction in patient’s past history  or EF  of 
50% at time of HCT  1  
Inflammatory bowel 
disease  Crohn’s disease or ulcerative colitis requiring treatment in 
the patient’s past history  1  
Diabetes  Requiring treatment with insulin or oral hypoglycemic, but 
not diet alone, at time of HCT  1  
Cerebro -vascular 
disease  Transient ischemic attack or cerebro -vascular accident in 
patient’s past history  1  
Psychiatric 
disturbance  Depression/anxiety requiring psychiatric consult or 
treatment at time of HCT  1  
Hepatic – mild Chronic hepatitis, Bilirubin >ULN - 1.5 X ULN, or 
AST/ALT >ULN -2.5XULN at time of HCT  1  
Obesity  Patients with a BMI of  
>35 for adults or with BMI -for-age percentile of ≥  95th 
percentile for children  at time of HCT 1  
Infection  Documented infection or fever of unknown etiology 
requiring anti -microbial treatment before, during and after  
the start of conditioning regimen  1  
Rheumatologic  SLE, RA, polymyositis, mixed CTD, polymyalgia 
rheumatica in patient’s past history   2  
Peptic  ulcer  Requiring treatment in patient’s past history  2  
Renal  Serum creatinine >2 mg/dl, on dialysis, or prior renal 
transplantation at time of HCT  2  
Moderate pulmonary  DLco and/or FEV 1 >65% -80% or  
Dyspnea on slight activity at time of HCT  2  
Prior solid tumor  • Treated at any time point  in the patient’s past 
history , excluding non -melanoma skin cancer  3  
Heart valve disease  At time of HCT excluding mitral valve prolapse  3  
Severe pulmonary  DLco and/or FEV 1 65% or  
Dyspnea at rest or requiring oxygen at time of HCT  3  
Moderate/severe 
hepatic  Liver cirrhosis, Bilirubin >1.5 X ULN, or AST/ALT 
>2.5XULN at time of HCT  3  
Please provide ( KPS): 
 Karnofsky Performance Score = _______%  Total 
Score  
=________  Signature of 
Provider:  
________________  
 
2546.00  - Nonablative  
91 
FHCRC Current Version:  02/06/2018  
 
 †One or more vessel -coronary artery stenosis, requiring medical treatment, stent, or bypass graft.  
EF indicates ejection fraction; ULN, upper limit of normal; SLE, systemic lupus erythmatosis; RA, rheumatoid 
arthritis; CTD, connective tissue disease; DLco, diffusion capacity of carbon monoxide; FEV 1, forced expiratory 
volume in one second; AST, aspartate aminotransferase; ALT, alanine aminotransferase . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 